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 The overall structure of macrocycles is intimately linked to its biological activities 
and chemical reactivities. Delineating the factors that control the macrocycle structure 
will be very useful in developing novel probes, therapeutics and chemical 
transformations. Using a systematic strategy with the [13]-macrodilactones as model 
system and a combinational of X-ray crystallography and computational methods, a 
general model that explains the effect of stereogenic elements (stereogenic centers and 
stereogenic plane) on the overall structure (planar chirality, shape and topology) of the 
[13]-macrodilactone was constructed. A specific geometrical arrangement in the 
stereogenic centers set the planar chirality (either pS or pR), shape (either ribbon or 
alternate) and consequently, the overall topology of substituted [13]-macrodilactones. 
This specific geometrical arrangement is fundamentally governed by the preference of 
the substituents to be in pseudo-equatorial position. The general model constructed has 
useful implications in synthesizing macrocycles with designed structural properties and in 
optimizing the biological and pharmacological activities of bioactive macrocycles. 
 The cardiac glycosides ouabain and digitoxin, established Na
+
/K
+
 ATPase 
inhibitors, were found to inhibit MDA-MB-231 breast cancer cell migration through an 
unbiased chemical genetics screen for cell motility. The Na
+
/K
+
 ATPase acts both as an 
ion-transporter and as a receptor for cardiac glycosides. To delineate which function is 
related to breast cancer cell migration, structure–activity relationship (SAR) profiles of 
cardiac glycosides were established at the cellular (cell migration inhibition), molecular 
(Na
+
/K
+
 ATPase inhibition), and atomic (computational docking) levels. Correlation of 
SAR profiles across these assays established links between cellular activity and specific 
protein–small molecule interactions. The antimigratory effect in MDA-MB-231 breast 
cancer cells are directly related to the inhibition of Na
+
/K
+
 transport. Specifically, the 
orientation of cardiac glycosides at the putative cation permeation path correlates with the 
Na
+
 pump activity and cell migration. Other Na
+
/K
+
 ATPase inhibitors that are 
structurally distinct from cardiac glycosides also exhibit antimigratory activity, 
corroborating the conclusion that the antiport function of Na
+
/K
+
 ATPase and not the 
receptor function is important for supporting the motility of MDA-MB-231 breast cancer 
cells. Correlative SAR can establish new relationships between specific biochemical 
functions and higher-level cellular processes. 
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Rules of macrocycle topology: a [13]-macrodilactone case study 
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1.1 Introduction 
 Macrocyles – cyclic molecules of 12 or more atoms – have a staggering array of 
structural diversity and biological activities (Fig. 1-1).  Ring size can range from 12 to 
50+ atoms with chemical composition that can vary from simple repeating units (i.e. 
ether linkages and amides) to complex combinations of various functional groups 
(alkenes, carbonyls, ethers etc.) in the ring and substituents. This huge structural diversity 
(both natural product and synthetic) is reflected to the wide-range of biological activities 
(anticancer, antibiotic, antifungal, antiparasitic, antiviral, immunomodulatory) that 
macrocycles can modulate as well as the enormous protein families it can target with 
disparate mechanisms of action. As evidenced by the long-standing history of the utility 
of natural product and synthetic macrocyles as drugs and their unique ability to modulate 
various biological activities, macrocycles hold real promise for developing new chemical 
probes and novel therapeutics1. 
 
 
 
 
 
 
 
 
 
 
Fig. 1-1. Examples of macrocycles 
 3 
1.2 Macrocycle and its unique chemical space 
  As a direct consequence of the lower number of freely rotatable bonds, the 
macrocyclic ring provides a high degree of conformational pre-organization - one 
of the unique and key structural features of macrocycles. With respect to target 
engagement of biologically active macrocyles, the conformational pre-organization 
of the ring can be used to strategically orient pharmacophoric groups3 and limit 
conformational entropy loss upon target binding4. This results in higher affinity 
and better selectivity towards specific members of a protein family or even 
between different isozymes. Macrocycles also display drug-like physicochemical 
and pharmacokinetic properties despite deviating from conventional rules of drug-
likeness. The next few paragraphs explain how conformational pre-organization 
brought about by macrocyclization can generate ligand efficient molecules with 
enhanced biological and pharmacokinetic properties.  
  
1.2.1 The effect of macrocyclization on potency  
  Conformational pre-organization that results from macrocyclization can 
improve the potency of acyclic molecules primarily through limitation of the 
entropic penalty of forming an inhibitor-protein complex. A molecule needs to 
adopt a specific conformation to successfully bind to a protein. Both acyclic and 
cyclic molecules can adopt such a bioactive conformation and thus the difference 
in the enthalpic contribution to binding is relatively small. However, in contrast to 
acyclic molecules, macrocyles have a limited number of conformations (due to 
restricted internal bond rotation) and thus have lower entropic penalties when 
 4 
changing from unbound to bound state. This contributes to a higher affinity and 
better potency. One compelling example of the effect on potency enhancement of 
macrocyclization is the macrocyclization of an acyclic small molecule 1-1 – a 
close analog of an inhibitor of farnesyltransferase that is in clinical trial as an 
anticancer drug5 (Fig. 1-2). Using transfer nuclear Overhouser effect (trNOE) 
NMR, it was observed to be in a folded conformation, which suggests that 
macrocyclization, might be beneficial for improving its potency. Indeed, the 
cyclized analog 1-3 is 20-fold more potent than the lead 1-1 and impressively 
55,000-fold more potent than its direct acyclic counterpart 1-2.  
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Fig. 1-2. Improving potency through macrocyclization. Two lowest energy 
conformations of 1-1 (lower left), consistent with trNOE NMR structure of its 
complex with farnesyttransferase, showed it exist in folded form. Rigidification 
through macrocyclization (lower right) greatly improved its potency where the 
macrocycle 1-3 is 50,000-fold more potent than its direct acyclic counterpart 1-2. The 
two figures for the macrocycle conformation were reused with permission. 
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1.2.2 The effect of macrocyclization on selectivity  
  Besides improvement in potency, macrocyclization can also vary the 
selectivity profiles of acyclic molecules by fixing or at least reducing the number 
of target-specific conformations. By taking advantage of the small difference in 
binding site topology between specific members of a protein family or between 
various isozymes6, an enhancement in selectivity can be obtained by using the 
macrocyclic ring as a scaffold to strategically orient pharmacophoric 
functionalities at specific three-dimensional locations. A great example is the 
development of selective kinase inihibitors (Fig. 1-3)7, one of the most challenging 
goals in drug discovery. The notoriously non-selective pan ATPase inihibitors 
staurosporine 1-4 and rebeccamycin 1-5 can be made selective by disrupting the 
planarity of indolocarbazole lactam ring system - the key pharmacophore of kinase 
inhibitors which acts as a mimic of ATP adenine ring. By breaking the central 
aromatic ring and controlling the kinase inhibitor’s conformation using various 
ring size, Warriner and colleagues developed selective kinase inhibitors with a C2-
symmetric anti conformation 1-6 (selective towards cAMP-dependent protein 
kinase/ protein kinase G/ protein kinase C (AGC)  group of protein kinases such as 
PKCs) and distorted syn conformation 1-7 (selective towards GSK3β)7.  
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1.2.3 Improving pharmacological and pharmacokinetic properties through 
macrocyclization  
  Since poor membrane permeability and metabolic instability are primarily 
due to conformational flexibility, restricting the conformational landscape and 
fine-tuning the orientation of H-bonding functionalities can significantly enhance 
Fig. 1-3. Improving selectivity and controlling small molecule conformation 
through macrocyclization. (a) Pan ATPase inhitors staurosporine 1-4 and 
rebeccamycin 1-5 were made selective through macrocyclization. Ring size 
controls the ratio of anti 1-6 and syn 1-7 conformations, which then controls its 
selectivity towards specific members of kinases. (b) Docked complex formed by 
a protein kinase with inhibitors in various conformations showing how fine-
tuning of macrocyclic conformation can allow access to selective inhibitors. The 
macrocycle-protein complex was reused with permission. 
 
a) b) 
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the pharmacological and pharmacokinetic properties of bioactive molecules. As an 
example, for diasteromeric cyclic peptides 1-8 and 1-9 (Fig. 1-4), the most 
permeable diastereomer 1-8 adopts a pseudo-symmetric conformation with 
internally satisfied hydrogen bonds while the less permeable diastereomer 1-9 
adopts a twisted conformation with some H-bonding groups oriented toward the 
solvent8. This demonstrates the effect of macrocyclic conformation in membrane 
permeability where molecules that can adopt conformations with internal H-bonds 
have better passive membrane permeability. Besides locking a specific 
conformation, macrocyclization of linear peptides can lead to structural changes 
that result in endopeptidase-resistant molecules9. This addresses one of the major 
limitations of linear peptides: their susceptibility to undergo proteolysis in the cell 
and in the blood. 
 These are but a few examples (among many reported in the literature)1a, 1d of the 
potential of macrocycles and the advantages of macrocyclization for drug 
development. Surprisingly, orally administered macrocyclic drugs such as 
cyclosporine A, tacrolimus and rapamycin are outside the window of what is 
generally considered to be drug-like properties10 i.e. their molecular weights are 
often > 500-900 g/mol and their number of H-bond donors (>5) and acceptors 
(>10) and polar surface area (>140) are beyond the accepted drug-like spectrum11 
(Table 1). Either these bioactive macrocycles are exceptions to the current standard 
for drug-like molecules or understanding the unique properties of macrocycles that 
brought about these favorable overall pharmacokinetic properties could open up 
new rules for developing therapeutic molecules. This avenue has been recently 
 8 
explored by Whitty and colleague who analyzed the binding modes of various 
macrocycle-protein complexes and proposed some useful guidelines for designing 
synthetic macrocycle libraries with structural and physicochemical features that 
will likely have high affinity to protein targets and good bioavailability12.  
 
           
  
 
 
 
 
 
 
 
 
 
 
 
Fig. 1-4. Effect of macrocyclic conformations in membrane permeability. 
NMR structural analysis showed that the hydrogen-bonding network in 
diastereomer 1-8 (H-bonds are internally satisfied due to a pseudo-
symmetric conformation) made it more permeable than distereomer 1-9 
(some hydrogen-bondng groups are oriented to the solvent due to an 
irregular twisted conformation). The macrocycle conformations are reused 
with permission. 
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Table 1-1. Examples of orally-administered macrocyclic drugs that don’t have drug-like 
properties. 
 
Orally-
administered 
macrocyclic 
drug 
MW 
(da) 
H-bond  
donor 
H-bond 
acceptor 
Polar surface 
area 
Cyclosporin A 1203 5.2 12 279 
Tacrolimus 804 3.3 3 178 
Rapamycin 914 4.3 13 195 
 
 
1.2.4 Macrocyles can modulate difficult therapeutic targets  
 In addition to the upsides of macrocyclization in optimization of biological and 
pharmacological properties of molecules, the huge interest in macrocycles is motivated 
by their ability to address targets often inaccessible to both standard small molecules and 
biologics - the most highly studied of which is the protein-protein interaction13. One of 
the various mechanisms by which macrocyles modulate protein-protein interactions is 
through either stabilization or destabilization of protein complexes. For example, 
epothilone B and its lactam analog Ixabepilone (an antibreastcancer metastasis drug) 
stabilize the α-β tubulin dimer14 while halichondin B and its analogs disrupt the 
microtubule dynamics by destabilizing these tubulin dimers15. Another mechanism is 
through direct structural modification of protein topologies. For example, the cyclic 
peptide spiramycin and the macrolide antibiotics erythromycin and carbamycin narrow 
the ribosome’s exit tunnel by binding to the inner surface of the ribosomal tunnel16.  
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1.2.5 Summary  
 Clearly, the unique structural properties of a macrocycle allow it to occupy a 
chemical space distinct from other molecules or its acyclic counterpart.  Conformational 
pre-organization provided by limited bond rotation of the ring can be harnessed to 
significantly improve not just the potency and selectivity of biologically active molecules 
but its pharmacological and overall pharmacokinetic properties as well. Macrocylization 
has provided an alternative strategy that medicinal chemists can use to optimize 
compound structure more suitable for development as pharmaceuticals. Most macrocyclic 
drugs do not fall into the standard categories of drug-like molecules. Understanding how 
these macrocycles work can introduce new parameters or rules for developing drugs as 
well as deepen our understanding of basic cellular processes such as the mechanisms of 
cell permeability.  Macrocycles have successfully demonstrated their ability to modulate 
difficult targets inaccessible to either standard small molecules or biologics. Besides 
expanding the repertoire of chemical space available for development of probe molecules 
or drugs in the otherwise crowded-area of enzymatic inhibition, macrocycles also opened 
up new biological targets such as protein-protein interaction surfaces. This provided more 
options for therapeutic interventions and more areas to explore for mining information on 
basic biological and cellular processes. Moreover, the initial efforts in drug discovery 
programs such as screening for biologically active molecules can greatly benefit from the 
inclusion of macrocyles with various ring scaffoldings in the chemical library screened. 
At the heart of all the benefits of macrocyle in medicinal chemistry, basic biology and 
drug discovery is the ability to use the macrocyclic ring as a scaffold to strategically 
orient pharmacophoric moieties and H-bonding functionality in three-dimensional space. 
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If macrocycles as a class is to live up to all its potential, deeper understanding of all the 
factors that contribute to the conformational pre-organization of macrocyclic ring needs 
to be clearly established. The next sections will specifically discuss the (1) implications 
of macrocyclic conformation to its biological activities and chemical reactivities and (2) 
the factors that affect macrocylic conformations. 
 
1.3. Biological and chemical consequence of macrocycle conformation 
 The overall structure of a macrocycle, specifically its ring conformation, is 
critical to its biological activity and chemical reactivites. The conformation of the 
ring controls the orientation of reactive functionalities and H-bonding groups in the 
macrocycle8. Thus, the upsides of macrocylization mentioned in the previous 
subsections, i.e. improved binding affinity, better selectivity and paharmakokinetic 
properties are intimately linked to ring conformation. In fact, macrocyclization of 
acyclic small molecules is only effective if the cyclization results to ground state 
cyclized conformation that approximates the optimal bound conformation5. In 
addition to the importance of ring conformation to the biological activities of 
macrocycles, the overall topology (ring conformation and planar chirality) of 
macrocyles is also critical to the stereoselectivity of reactions involving its 
functional groups. This is illustrated by examples of macrocyclic diasstereocontrol 
and transannular transformations – two useful tools for asymmetric synthesis of 
macrocycles and polycyclic compounds. Understanding the factors that affect the 
conformation of macrocycles, therefore, is highly important. The next paragraphs 
 12 
will discuss, in more detail, the contribution of macrocyclic ring conformation to 
the biological activities and chemical reactivities of macrocycles.  
 
1.3.1 Effect of macrocyclic conformations to biological activities 
  The majority of the improvement in potency, selectivity and overall 
pharmacological and pharmacokinetic profile brought about by macrocyclization 
can be attributed to macrocyclic ring conformation. Macrocyclization of acyclic, 
biologically active molecules is only effective if the correct spatial arrangement of 
key binding groups or reactive functionalities is maintained. A direct example of 
the effect of conformation in selectivity is illustrated by the macrocyclization of 
the pan-ATPase inhibitors staurosporine and rebeccamycin described previously. 
Upon, macrocyclization, the C2-symmetric anti conformation is selective towards 
the AGC protein kinase group such as PKC while the distorted syn conformation is 
selective towards glycogen synthase kinase 3β (GSK3β). Another compelling 
example of the contribution of macrocyclic ring conformation in both biological 
and physicochemical properties is illustrated by a comprehensive SAR study of a 
HSP-90 inhibitor by a group of scientists from Pfizer17 (Fig. 1-5). 
Macrocyclization 1-11 of an anticancer clinical candidate 1-10 gave better 
biological activity. Furthermore, simple addition of a methyl group 1-12 resulted in 
better pharmacological activities. There are plenty more reports in the literature 
that demonstrates the huge contribution of the structural features of macrocyclic 
ring to the biological activities of macrocycles1a. What is not clear though is how 
specific structural features such as the stereogenic elements on the ring (i.e 
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stereogenic centers and stereogenic axis and planes) affect the conformation of 
bioactive macrocycles. 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1-5. The shape of the macrocycle is important to its biological activity. 
Rigidified version 1-11 of acyclic anticancer clinical candidate 1-10 improved 
its biological activity. Simple addition of a methyl group 1-12 with a specific 
chirality improved its physiological activity. The methyl group does not seem to 
interact with any key amino acids around the binding site (as shown by the co-
crystal structure of 1-12 bound to HSP-90) suggesting that the improvement in 
pharmacological activity might be due to changes in ring conformation induced 
by the added methyl group. The co-crystal structure was reused with 
permission. 
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1.3.2 Effect of macrocycle conformation on its chemical reactivities    
  Macrocycles undergo unique chemical transformations such as macrocyclic 
diastereocontrol and various transannular reactions where the fate of the 
transformation is governed by the ground state conformation of the macrocycle. 
 
1.3.2.1 Macrocyclic stereocontrol 
  In Still’s pioneering work, alkene-containing macrocycles undergo highly 
stereoselective reactions termed macrocyclic stereocontrol18. This control is 
primarily due to the orientation of alkene plane (which is perpendicular to the 
molecular plane) and thus only one face is accessible to reagents leading to highly 
stereoselective reactions (Figure 1-6a). Furthermore, addition of one or two methyl 
groups at different positions around the ring can significantly affect the 
stereochemical outcome of the reactive functionalities on the ring. Macrocyclic 
stereocontrol has been used in a number of key transformations in the synthesis of 
natural products. Examples include the total synthesis of cladiellin, a marine 
natural product where the key transformation is the diastereoselective 
dihydroxylation of trisubstituted olefin without the use of assymetric reagent19. 
Another example is the synthesis of neopeltolide in which the key transformation 
is the stereoselective hydrogenation controlled by the ground state conformation of 
the macrocycle20 (Fig. 1-6b).  
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1.3.2.2 Transannular transformations 
  Relatively flexible macrocycles on the other hand, can undergo transannular 
interactions leading to intramolecular collapse to form polycyclic molecules (Fig. 
1-7). One example is Baran and colleague’s Palau’amine synthesis in which the 
macrocycle conformation of macropalau’amine allowed for the desired 
transannular reaction leading to the hallmark trans-5,5 ring system21 (Fig. 1-7a). 
Fig. 1-6. The shape of the macrocycle is important to its chemical reactivity as 
illustrated by macrocyclic stereocontrol. (a) Macrocycyclic stereocontrol is 
brought about by the perpendicular orientation of the alkene plane relative to the 
molecular plane. (b) Synthesis of neopeltolide natural product showing the 
macrocyclic diasstereocontrol as the key transformation.  
 
a) 
b) 
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Another example is the olefin isomerisation/intramolecular conjugate addition 
reported by Porco and colleague to get a tricyclic ring systems accessed via 
transannular cyclization of macrocyclic bis-lactams22 (Fig. 1-7b). The last example 
in Fig. 1-7 shows the tandem oxy-Cope/ene reaction reported by Bariault and co-
worker where the E-olefin geometry of the macrolactone intermediate gave an 
exclusive trans ring junction. Furthermore, the more stable ground-state chair-like 
conformation of the trans-annular ene reaction transition state resulted to the 
preferential formation of the observed tricyclic product23 (Fig. 1-7c).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1-7. The shape of the macrocycle is important to its chemical reactivity as 
illustrated by transannular interactions.  
 
a) 
b) 
c) 
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1.4 Factors that affect the conformation of macrocycles 
 The previous two sections illustrated the contribution of the unique structural 
features of macrocycles to its biological and chemical reactivities with emphasis 
on the ring conformation as a critical structural feature. The discussion was meant 
to explain the motivation behind the importance of understanding, at a 
fundamental level, all the factors that affect the stable conformation adopted by the 
macrocyclic ring, which is the main goal of our investigation. To put our work into 
proper perspective in the field of structural analysis of macroycles, this subsection 
will review the current understanding of the factors that control macrocyclic 
structure. 
 A given macrocycle can exist in various stable conformations but only a few are 
low enough in energy to be accessible at room temperature. In general, 
conformational biasing in macrocycles is governed by their tendency to minimize 
transannular nonbonded repulsions. For macrocycles with various substitutions and 
unsaturated groups such as alkenes, esters and amides, the rules with respect to 
stable conformations adopted by the skeleton are more complex. Factors such as 
ring size, chemical composition of the ring skeleton (type and arrangement of 
functional groups, unsaturation, and planar units) and configuration of stereogenic 
elements (stereogenic planes and stereogenic centers around the ring) exert 
considerable contributions to the macrocycle conformation.    
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1.4.1 Conformational analysis of 14-membered macrocyles  
  The 14-membered macrocycles are one of the most highly studied systems 
due to the prevalence of 14-membered bioactive natural products24. According to 
Dale’s pioneering work, 14-membered macrocycles should exist predominantly in 
a ‘rectangular’ diamond-lattice [3434] conformation25 (Fig. 1-8b,c). Dale’s 
analysis showed that cyclotetradecane is the first cycloalkane after cyclohexane 
that can have a strain-free conformation in the form of a diamond-lattice [3434]. It 
is composed of two ‘three-bond’ sides and two ‘four-bond’ sides, hence the name 
[3434]. Indeed, cyclotetradecane exists only in this [3434] conformation in solid 
state as supported by XRD26 and solid state 13C NMR27. In liquid state however, it 
loses its conformational homogeneity and exists in several conformations with the 
[3434] conformation being the most predominant one as supported by low temp 
NMR analysis28, and vibrational spectroscopy29. 
 
 
 
 
 
 
 
 
 
 
a) b) c) 
Fig. 1-8. Representations of cyclotetradecane. (a) Chemdraw 2D representation.  
(b) Dale’s [3434] representation of triangular diamond-lattice conformation 
where torsion angles are represented as positive and negative numbers. (c) 
Schematic drawing of the actual crystal structure of cyclotetradecane from 
reference 25.  
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 Dale also predicted that replacing the methylene groups in the 
cyclotetradecane ring with an oxygen atom or groups such as an amine, carbonyl 
or imine would cause only minimal perturbation on the diamond-lattice 
conformation. Indeed, 1-oxa-30, 1,3,8,10-tetraoxa-31, 1,8-diaza-32, 
cyclotetradecanone33, cyclotetradecane-1,8-dione34, and tridecanolactone34 gave 
the same [3434] diamond-lattice conformation. Moreover, insertion of either a 
ester35 or amide36 group into the ring gave the same [3434] conformation as the 
most stable conformation and with the lactam and lactone groups in s-trans 
conformation25  in both solution35 and solid state36b.   
 More complex 14-memebered macrocycles with various substitutions and in 
combination with either a amide28 or ester35 group in the ring gave a more complicated 
correlation between substitution pattern, planar units (lactam or lactone) and macrocyclic 
conformation. Dale’s analysis predicted that substitutions on 14-memberd macrocycles 
would not affect the preferred diamond-lattice [3434] conformation. Moreover, he 
predicted that the substituents could only occupy exterior (pseudo-equatorial) positions 
due to large transannular interaction associated with interior (pseudo-axial) position. 
Indeed, substituents around 14-membered macrocycles only occupy exterior positions. 
However, certain substituted 14-membered macrocycles did not adopt the [3434] 
conformation28, 35. Highly substituted 14-macrolides gave a different lowest energy 
conformation (i.e., [3335], [3344] etc.) distinct from the predicted [3434] conformation as 
supported by both XRD and molecular mechanics calculation35 (Fig. 1-9). The 
conformation seemed to depend on the number and configuration of substitutions and the 
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substitution pattern. Similarly, using various techniques in both solid and liquid state, 
conformational analysis of 14-membered diketal dilactam36a painted a more complex 
relationship between planar units, stereogenic centers and conformation. In this ring 
system, the conformations depend on whether the macrocycle is chiral or achiral and on 
the stereochemistry of the substituents. Based on these reports, the rules governing the 
conformational preference of highly substituted 14-macrocycles are more complex than 
what Dale’s analysis predicted. The substituents around the ring clearly affect the stable 
conformation adopted by the 14-membered macrocycle where various conformations 
distinct from the diamond-lattice [3434] conformation can be accessed depending on the 
number and configuration of stereogenic centers and the substitution pattern. How these 
stereogenic elements control the conformation of macrocycles, however, is not currently 
understood.  
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[3434] 
[34’3’4’] 
[3335] 
[3344] 
Fig. 1-9. Chemdraw and Ortep diagram of substituted 14-macrolides that adopted 
various conformations, with some that are distinct from the diamaond-lacttice [3434] 
conformation. The conformation seemed to depend on the number and configurations 
of stereogenic center around the ring and the substitution pattern. 
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1.4.2. Structural properties and conformational analysis of 13-membered 
macrocyles  
  Although they have not been investigated as thoroughly as 14-membered 
ring systems, 13-membered macrocyles have unique structural features. One report 
(among few) showed that in contrast to strained 12-membered cyclic tetrapeptides 
(CTPs), 13-membered CTPs can adopt a unique architecture that is more rigid, 
easier to cyclize, hydrolytically more stable and are conformationally homogenous 
in polar solvents37 (Fig. 1-10). 12-membered CTPs have unfavorable strain due to 
the four trans-amide bond restraints. Addition of a methylene to a 12-membered 
ring CTPs by using a β-amino acid rotates one of the amide bonds that results to a 
more rigid structure. Because of the conformational homogeneity of 13-membered 
CTPs, 13-membered versions of the 12-membered natural product apacidin 
(HDAC inhibitor) were used to mine three-dimensional pharmacophoric features 
necessary for designing isoform-selective HDAC inhibitors38. These studies 
illustrate the potentials of the unique structural features of 13-membered 
macrocyles and reiterate the importance of understanding macrocyclic 
conformation in developing useful probe molecules.  
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 Compared to 14-membered macrocycles, the conformational preference of 
13-membered macrocycles is less understood probably because of the lesser 
population of bioactive 13-membered macroyclic natural products24. A couple of 
studies on stevastelins – a 13-membered antiviral cyclic peptide that targets 
Vaccinia VH1 phosphatase – looked at the conformations in solution of a series of 
its diastereomeric analogs (Fig. 1-11). Using force field conformational searches 
for one force field constrained by variables from the NMR data, one report found 
that these diastereomers exist as a single conformational family in solution39 (Fig. 
1-11b). Using another method, NMR analysis of molecular flexibility in solution 
(NAMFIS), the same set of diastereomers were found to adopt different 
conformations in solution40 (Fig. 1-11c). The accuracy of conformational analysis 
of macrocycles using NMR and computational methods is highly dependent on the 
type of conformational search methods used (different search methods have 
different parameters) and the condition and type of NMR analysis. Although the 
two studies found contradictory results between the homogeneity and 
Fig. 1-10. 13-membered analogs 1-14 of the 12-membered natural product 
Apacidin 1-13 are conformationally homogenous in solution. The figure for the 
conformation of 13-membered macrocycle was reused with permission. 
 
= 
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heterogeneity of the conformations of the studied series of diatereomers in solution, 
both agreed that using D-ser reduces conformational mobility in stevastelins and 
more importantly, subtle changes in stereochemistry at one or two chiral centers 
can greatly affect the conformational preference of this 13-membered macrocycles. 
Similar to 14-membered macrocycles, the specific contribution of configuration at 
a stereogenic center or combination of stereogenic centers and substitution pattern 
to the low energy conformation adopted by the macrocycle is not well understood. 
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1.5 [13]-macrodilactone: motivation, research question, hypothesis, research 
design and strategy  
 
1.5.1 Motivation and research question  
 As emphasized in the introduction, macrocycles as a class of molecules have 
unique structural properties that allow them to occupy a chemical space distinct from 
other molecules or their acyclic counterparts. This unique chemical space has great 
potential in biology (developing novel chemical probes, and therapeutics) and chemistry 
(developing novel chemical transformations and asymmetric reactions). The unique 
structural properties are intimately linked to ring conformation. Thus, understanding the 
factors that control the conformation of the ring will be very useful. Dale’s pioneering 
work on 14-membered macrocycles greatly simplified its conformational analysis but is 
not applicable to more complex, highly substituted 14-membered macrocyclic systems. 
13-membered macrocycles, although possess interesting structural and biological 
properties are less studied. In both 13-membered and 14-membered macrocycles or 
probably, in macrocycles as a class in general, one of the important areas that need 
clarification is how the stereogenic elements (stereogenic planes and stereogenic centers 
around the ring) contribute to the stable low-energy conformation adopted by the 
macrocyle. Although, many have observed that subtle changes in the stereochemistry in 
one or two chiral centers have tremendous impact on conformation, as far as we know, no 
one has figured out how this happens. We think that this is because most of the reports 
used macrocyclic systems with multiple stereogenic centers already set in the ring. Such 
is the case for cyclic peptides, which is the macrocyclic system used by majority of 
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scientists who work in this field. We thought that in order to really understand the 
contribution of stereogenic centers on macrocyclic conformation, a systematic study is 
required. Starting from a ring system without stereogenic center followed by systematic 
incorporation of one streogenic center at a time at specific position around the ring can 
help pinpoint the exact contribution of specific stereogenic center and combinations 
thereof. One of the overarching goals in our lab is to understand, at a fundamental level, 
all the factors that affect the overall structure of macrocycles.    
 
1.5.2 Hypothesis, research design and strategy 
  Currently, we use the [13]-macrodilactone as our model system to 
systematically explore the parameters that govern its structure. Consider the 
unsubstituted macrocycle 1-19 in Figure 1-12. Atoms of the ring are categorized as 
part of a planar unit such as the two esters (atoms C4-C7 and C12-C2) and the E-
alkene (C8-C11) or elsewhere (atom C3). Connections between planar units can be 
through a bond, as in the connection of the C4-C7 ester with the alkene, or through 
an atom (and its associated bonds), as between the two ester units which are 
connected by C3. Starting with the C12-C2 ester unit, a motif of planar unit, atom, 
planar unit, planar unit develops (Fig. 1-12).  
 We look at the contribution of the interplay between planar units (2 esters and an 
e-alkene) and stereogenic centers around the ring on its overall structure in solid state 
using X-ray crystallography. We describe the three-dimensional structure of the [13]-
macrodilactone using three terms - planar chirality, shape and topology. The planar 
chirality refers to the configuration of the embedded stereogenic E-alkene plane. We use 
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shape to describe the conformation or geometry adopted by the ring skeleton regardless 
of the substituents. We use topology as a more encompassing description of the overall 
structure of the [13]-macrodilactone because it takes into consideration all the structural 
features i.e., planar chirality, shape and the orientation of functional groups in the ring 
and in the substituents.  
 Our major hypothesis is that the numbered atoms (Fig. 1-12) – we call key atoms 
- that are positioned at the edge of each planar unit can greatly influence the overall 
topology of the macrocycle primarily due to steric considerations. If the configuration of 
a substituent at any of the key atoms results in ring strain, the planar units will rearrange 
themselves forcing the macrocycle to adopt a different shape. To test this hypothesis, we 
systematically incorporate one and two substituents at a time around the key atoms on the 
ring using a synthetic route we have previously reported – a series of acylation of various 
diol using various pentenoic acid followed by ring closing metathesis of the 
corresponding diene41. This systematic incorporation of stereogenic centers will allow us 
to determine the actual contribution of the configuration at one or a combination of 
stereogenic centers as well as the substitution pattern on the overall topology (planar 
chirality, shape and functional group orientations) of [13]-macrodilactone in solid state 
using X-ray crystallography. Using this strategy, we have previously reported a series of 
observations on mono-substituted41b, 41d and di-substituted 13-macrodilactones41c, 41d .  
 In this chapter, we construct a general model that explains the topology of our 
[13]-macrodilactones. The model collects the factors that govern the topology and offers 
a physical rationale behind them. Our analysis will focus especially on how the 
stereogenic centers at key atoms affect the topology of [13]-macrodilactones. We use a 
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combination of crystallographic data along with computational methods to categorize the 
topologies and to understand their origins. We think that our systematic approach to 
dissect the principles that govern the structural preference of [13]-macrodilactones will 
be helpful in synthesizing macrocycles with designed structural properties. Although our 
observations are primarily based on X-ray crystallographic data and some computational 
methods and are thus bound by the limitations inherent to these types of analyses, the 
fundamental information they revealed about the [13]-macrodilactone systems has value 
and might be applicable to other ring systems with similar chemical composition.  
 
 
  
 
 
 
 
 
 
 
 
 
 
Fig. 1-12. Research design and strategy 
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1.6 Unsubstituted [13]-macrodilactone: synthesis and structural analyses 
 Our goal has been to systematically assess the contributions of specific 
stereogenic centers on the topology of [13]-macrodilactones. All our previous reports 
were focused on substituted [13]-macrodilactones41b-d. To gain an understanding of the 
inherent conformational preferences of the macrocycle, however, we synthesized and 
characterized the unsubstituted [13]-macrodilactone 1-19. Its structure serves as a 
reference for comparison to all the subsequent substituted structures. In this way, we 
could assign the effect of the configuration of stereogenic centers at the key atoms on the 
overall structure of the [13]-macrodilactone. 
 
1.6.1 Unsubstituted [13]-macrodilactone: synthesis and X-ray crystal structure 
 The unsubstituted [13]-macrodilactone 1-19 was synthesized using the route we 
previously reported41b-d and characterized using X-ray crystallography. The starting 1,3 
propanediol was run though a series of acylation using pentenoic acid to get the 
diacylated diene 1-18. This acyclic precursor was closed via a ring closing metathesis 
using Grubb’s 2nd generation catalyst (Scheme 1-1).    
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Scheme 1-1. Synthesis of [13]-macrodilactone 
  
  Unsubstituted [13]-macrodilactone 1-19 is crystalline and its structure was 
characterized using X-ray crystallography. Like the other [13]-macrodilactones we 
previously reported, 1-19 is rigidified by three four-atom planar units: two ester 
planes of atoms 4,5,6,7 and 2,3,12,13 and the alkene plane of atoms 8,9,10,11. 
These planar units limit the number of freely rotatable bonds in the macrocyle (Fig. 
1-12 and 1-13). The planar units arranged themselves in a non-coplanar manner 
around C3, an sp3-hybridized carbon that is not a part of any planar units. This 
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atom is called a hinge atom because it acts as a hinge in which the two ester planes 
can rearrange themselves. The macrocycle adopted a shape that, when viewed 
from the side, looks like a ribbon and, from the top, looks like a triangle (Fig. 1-
13). We call this shape ‘ribbon’ because the planar units wrap around each other in 
a manner that resembles a ribbon. This result establishes that the globally preferred 
shape for the [13]-macrodilactone is the ribbon shape. Importantly, 1-19 
crystallized as a racemic mixture of enantiomeric macrocycles that exhibit planar 
chirality (Figs. 1-13, 1-14). E-alkene containing cyclic molecules such as E-
cycylooctene shows planar chirality that is solely due to the streogenic E-alkene 
plane. Planar chirality in macrocycles was also observed for bisbenzimidazole 
macrocycles with chiral cyclic E-alkene linkage that hardly flips into its 
enantiomeric structure at room temperature42. Furthermore, for bisbenzimidazole 
macrocycles, the E-alkene planar chirality was effectively transferred to the S axial 
chirality of the bisimidazole framework and the P helical chirality of the cyclic E-
alkene43. Both pS and pR planar chiral macrocycles - the planar chirality was 
assigned based on the configuration of the chiral E-alkene plane (Fig. 1-14) - are 
present in the unit cell for 1-19, proving that the [13]-macrodilactone motif creates 
an element of stereogenicity on its own.  
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Fig. 1-13. Structural properties of unsubstituted [13]-macrodilactone. Crystal structure 
show the planar enantiomers - pS and pR. Numbered atoms  show the three 4-atom planar 
units. Top figures show the triangular shape when viewed from the top of the molecular 
plane. Bottom figures show the ribbon shape when viewed on the side of the molecular 
plane.  
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-14. Assignment of planar chirality of [13]-macrodilactones based on the 
configuration of the stereogenic alkene plane. 
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1.6.2 Introduction to 2D maps of [13]-macrodilactones 
In order to easily and systematically account for the similarities and differences in 
shape and planar chiralities between each [13]-macrodilactones, we have adapted a 
graphical representation previously developed for porphyrin systems44. The map shows 
the deviation of each atom from a molecular plane defined by three specific atoms: C3, 
C13 and C6. Deviations of each atom from the plane were measured using the software 
Mercury, available from CCDC. The y-axis corresponds to the relative distance of each 
atom with respect to the molecular plain and the positive or negative sign refers to the 
atoms above or below the specified plane (Fig. 1-15). Using the pS enantiomer of [13]-
macrodilactone 1-19 as an example (Fig. 1-15), the plane consisting of the C3, C13, and 
C6 (coded in black) atoms were chosen to define the macrocyclic plane. To respresent a 
three-dimensional structure in two-dimensions, the macrocyle was treated as an acyclic 
structure by cutting through the C3 atom. This leads to a two-dimensional map where the 
C2-C3 bond represented as the first 2 points on the graph followed by the succession of 
atoms that constitute the ring skeleton with the C4-C3 bond represented as the last points 
in the graph. The same treatment was used to graphically represent the crystal structures 
of all the [13]-macrodilactones. These maps help to simplify the visualization of the 
similarities and differences in the shape and planar chirality between various [13]-
macrodilactones that would otherwise require multiple figures to illustrate the different 
perspectives in looking at a three-dimensional structure.    
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Figure 1-15.  Construction of the 2D map of [13]-macrodilactone 
 
1.7 Mono-substituted [13]-macrodilactones: syntheses and structural analyses 
 To look at the effect of one stereogenic center on the topology (planar chirality 
and shape) of the [13]-macrodilactone, we synthesized mono-substituted versions (with 
stereogenic centers at either C2 or C7) and followed on the subsequent structural changes 
using X-ray crystallography. Our lab previously synthesized the C2-substituted [13]-
macrodilactone 1-20 and found that specific configuration at C2 gave a specific planar 
chirality where an R and S configuration gave a pR and pS planar chirality, 
respectively41b (Fig. 1-16). A new monosubstituted [13]-macrodilactone with a phenyl 
substitutent at C7 position was synthesized and characterized to look at the effect of 
incorporating a stereogenic center at the carbon alpha to the carbonyl41d.   
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Fig. 1-16. X-ray crystal structure of the enantiomers of C2-methyl [13]-macrodilactone 
1-20. 
 
1.7.1 C7 mono-substituted [13]-macrodilactone: Synthesis and X-ray crystal structure 
 C7-phenyl mono-substituted [13]-macrodilactone 1-22 was synthesized using the 
same synthetic route (Scheme 1-2) we established previously. 1,3- propanediol was first 
acylated with pentenoic acid using DCC and DMAP to yield the 3-hydroxypropyl 4-
pentenoate in 56% yield. A second acylation with racemic 2-phenyl-4-pentenoic acid on 
the remaining free hydroxyl group gave diacylated product (80%). Racemic macrocycle 
1-22 (rac-1-22) arose via RCM of the diacylated product using Grubbs’ second-
generation catalyst (58%).   
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Scheme 1-2. Synthesis of C7-phenyl [13]-macrodilactone 
 
 Similar to the C2-methyl compound 1-20, the configuration at the α-stereogenic 
center (C7) guides the topology of [13]-macrodilactones. Macrocycle rac-1-22 was 
isolated as a crystalline solid, which was subjected to X-ray crystallographic analysis. 
Since racemic 2-phenyl-4-pentenoic acid was used in the synthesis, the corresponding 
macrocycle was also racemic. Present in its crystal lattice, therefore, were both 
enantiomers of the [13]-macrodilactone 1-22. The C7 stereogenic center with R 
configuration resulted in a macrocycle with only pS planar chirality while the C7 S 
enantiomer gave rise to only pR planar chirality (Fig. 1-17). Transannular nonbonded 
interactions where sterically demanding substituents attached to the stereogenic center are 
situated away from the macrocyclic ring itself are minimized in this conformation. The 
enantiomers have the same shape but different planar chirality and, thus, different 
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topologies. Here, ‘topology’ includes the mirror-image orientations of the phenyl 
substituents and the carbonyl groups in three-dimensional space. It is important to note 
that the shape adopted by the backbone of 1-22 was similar to that of C2-substituted 
macrocycle 1-20 (RMSD = 0.0454, using 2R,pR-1-20 and 7S,pR-1-22) (Fig. 1-18), 
supporting that this shape is generally the most stable conformation for the mono-
substituted [13]-macrodilactones regardless of the location of the substituent (either C2 or 
C7) or the type of substituent (methyl or phenyl). Both C2 and C7 are at the junction of 
two planar units (Figure 1-12 and 1-13) corroborating the hypothesis that these positions 
are key stereogenic centers that direct the planar chirality, and hence the topology of 
[13]-macrodilactones. 
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Fig. 1-17. X-ray crystal structures of the enantiomers of C7-phenyl [13]-macrodilactone 
1-22. 
 
 
     
Fig. 1-18. Overlay of 2R,pR - 1-20 (pink) and 7S, pR - 1-22 (cyan) with an RMSD of 
0.0454 showing common ‘triangular’ or ‘ribbon’ [13]-macrodilactone shape. 
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1.7.2 Illustration of α-carbon stereogenic center’s control of planar chirality and 
demonstration of macrocyclic stereocontrol using chiral HPLC 
  
 To illustrate that it is indeed the configuration at the α-stereogenic center that 
dictates the planar chirality adopted by the [13]-macrodilactone, an enantioenriched 
version of 1-22 (7S,pR) was synthesized using 2S-phenyl-4-pentenoic acid (90% ee). 
Chiral HPLC profiles of rac-1-22 and 7S,pR-1-22 are shown in Fig. 1-19. The 
macrocycle derived from racemic pentenoic acid resulted in a 50:50 mixture of [13]-
macrodilactones. The one synthesized from 2S-phenyl-4-pentenoic acid was 
enantioenriched, with an ee of 60%. We attributed the deterioration of enrichment 
between the acid and macrocycle to racemization of the chiral diester under the acylation 
conditions during diene formation. Nonetheless, the transfer of point chirality from the 
starting acid to the planar chirality observed in macrocycle 7S,pR-1-22 corroborated our 
original conclusion about the control of planar chirality in [13]-macrodilactones by the α-
stereogenic center. DMDO epoxidation  of rac-1-22 (Scheme 1-3) gave only one 
diastereomer of 1-23 as a pair of enantiomers (Figure 1-19). For 7R,pS-1-22, the 
enantioenrichment of the alkene was maintained after epoxidation to 1-22. Reactions of 
these [13]-macrodilactones therefore exhibit a high level of macrocyclic diastereocontrol. 
 
     
Scheme 1-3. DMDO epoxidation of rac-1-22. 
O
O
O
O
Ph
O
Oxone, NaHCO3
DCM/H2O O
O
O
O
Ph
O
64 %
1-22 1-23
 41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1-19. Chiral HPLC profiles of racemic (pink) and chiral (blue) [13]-macrodilactone 
1-22 and the corresponding epoxides 1-23. 
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1.7.3 Structural insights on the effect of one stereogenic center on [13]-macrodilactone 
topology 
 
Table 1-2. Point chirality-to-planar chirality correspondence in mono-substituted [13]-
macrodilactones  
 
Mono-substituted 13-
macrodilactones Point chirality Planar chirality 
C2-methyl 2S pS 2R pR 
C7-phenyl 
(if phenyl is given the 3rd 
priority in assigning 
configuration) 
7R (7S) pS 
7S (7R) pR 
 
 
 The structures of the two mono-substituted [13]-macrodilactones (with a 
stereogenic center at either C2 or C7) demonstrated that the configuration at the 
center guides the planar chirality of [13]-macrodilactone where one configuration, 
either R or S only gave one planar chiral enantiomer, pS or pR. In the case of the 
C2-methyl [13]-macrodilactone 1-20, the 2R center gave rise to the pR planar 
chirality. For 1-22, the 7S configuration gave rise to the pR planar chirality. This 
observation is further supported by the fidelity of formation of only one planar 
chirality during cyclization of a homochiral diene. At first glance, it may seem that 
there is no correspondence between the configuration at the stereogenic center and 
the planar chirality of the macrocycle. However, if the substituent (methyl, phenyl, 
etc.) on the stereogenic center is given the third priority by convention, then the 7S 
configuruation of 1-22 becomes 7R (Table 1-2). It suggests that specific geometry 
of groups around the center (not necessarily equivalent to CIP R and S 
designations) does in fact set the planar chirality of the ring regardless of the 
substituent type (either methyl or phenyl) or location (either C2 or C7). If any 
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substituent on the ring will be given the third priority when assigning configuration 
at point chirality, then the rule for point-to-planar chirality in mono-substituted 
[13]-macrodilactone systems will be R-to-pR and S-to-pS (Table 1-2).  Moreover, 
the unsubstituted [13]-macrodilactone 1-19 and the two monosubstituted 1-20 and 
1-22 all adopted the same ribbon or triangular shape as illustrated by the 2D maps 
(Fig. 1-20). Also note that the substituents in 1-20  and 1-22  are all positioned 
outside of the ring or are in ‘pseudo-equatorial’ positions as evident in their crystal 
structure and in the 2D maps.    
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Fig. 1-20. 2D maps for the unsubstituted [13]-macrodilactone (a) 1-19 and mono-
substituted [13]-macrodilactones (b) 1-20 and (b) 1-22. 
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Å 
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1.7.4 Origin of the control of [13]-macrodilactone planar chirality by one stereogenic 
center 
 Since the unsubstituted [13]-macrodilactone 1-22 contains an inherent planar 
chirality (an element of stereoisomerism), addition of another stereogenic element 
such as a stereogenic center could give rise to up to four stereoisomers. Combining 
specific isomers with either pS or pR planar chirality for each R, S configuration at 
the stereogeic center would give pS,S, pS,R, pR,S, and pR,R isomers. In cases 
where the [13]-macrodilactone had only one stereogenci center, we only isolate 
two stereoisomers - a pair of enantiomers – in which each configuration (either S 
or R) at stereogenic center gave rise to only one out of the two possible planar 
chiralities (pS or pR). This observation hypothesized that the energy associated 
with the conformation of the two stereoisomers we didn’t isolate are higher energy 
conformations.  
Ground-state energy minimization - using a dispersion corrected density functional 
(MO6-2x) paired with a robust basis set (6-31+G(d,p)) - was employed to look at the 
energetics associated with the conformations of 1-20 and 1-22 (Fig. 1-21 and 1-22 ). The 
C7-phenyl group in 1-22 was replaced with a methyl group to have the same number of 
atoms when comparing the energies for each macrocyels. The planar stereoisomers of 1-
20 (2S, pS and 2R, pR) have degenerate energies and thus were isolated and crystallized 
as a racemate of planar enantiomers (Figs. 1-16 and 1-21). The other two stereoisomers 
(2S, pR and 2R, pS) that were not isolated (and probably were not formed) have 
degenerate energies as well but are 3.5 kcal/mol higher than their respective 
diastereomers (Fig. 1-21). The specific combinations of 2S, pR and 2R, pS results in a 
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macrocyclic conformation in which the substituents are both in pseudo-axial position as 
opposed to pseudo-equatorial positions of the substitutents of stereoisomers 2S, pS and 
2R, pR. A pseudo-axial position promoted transannular nonbonding interactions that 
resulted to a higher energy conformation. Similar observations were seen for the 
energetics of 1-22 but with a slightly lower energy difference (2.4 kcal/mol) between the 
isolated isomers (7R, pR and 7S, pS – with a methyl substituent instead of phenyl) and the 
other two potential isomers (7S,pR and 7R, pS - with a methyl substituent instead of 
phenyl) (Figure 1-22). It appears that for mono-substituted [13]-macrodilactones, 
regardless of substituent position (either C2 or C7) or type of substituent (either methyl or 
phenyl), the preference for a pseudo-equatorial position governs the selectivity for a 
specific planar chirality conferred by the configuration at the stereogenic center. 
Moreover, the shape adopted by the mono-substituted [13]-macrodilactones 1-20 and 1-
22 is the same triangular or ribbon shape observed for the unsubstituted [13]-
macrodilactone 1-20 showing that addition of one substituent in the ring does not affect 
the shape of [13]-macrodilactones. 
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Fig. 1-21. Ground-state energy minimizations of conformations of four 
stereoisomers of 1-20. 
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Fig. 1-22. Ground-state energy minimizations of conformations of four stereoisomers of 
1-22 with a methyl substiuent instead of phenyl. 
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1.8 Di-substituted [13]-macrodilactones: syntheses and structural analyses 
  
 Subtle changes in stereochemistry of substituents can greatly influence the 
conformational preference and biological activities of macrocyles as discussed in the 
introduction. This observation has confounded medicinal chemists for a long time. Our 
systematic approach in using the [13]-macrodilactone systems lends itself to the 
possibility of addressing how the stereogenic centers around the macrocyle contributes to 
its overall structure. To explore some underlying principles on the effect of combinations 
of two stereogenic centers and substitution pattern on the planar chirality, shape and 
overall topology of [13]-macrodilactones, we used the same synthetic route we have 
previously reported to synthesize di-substituted macrocycles with various substitution 
patterns. 
  
Fig. 1-23. Di-substituted [13]-macrodilactones with various substitution patterns. From 
left to right: 7,12; 2,4; 2,7; 2,12 di-substituted 13-macrodilactones.  
 
1.8.1 C7, C12 - diphenyl [13]-macrodilactones: synthesis and X-ray crystal structure 
 C7 and C12 di-substituted [13]-macrodilactoens were synthesized to explore how 
the α-stereogenic centers work together to guide both the shape and topology of [13]-
macrodilactones. They were prepared in the same reaction pot because the diastereomeric 
RCM precursors, an enantiomeric pair and a meso compound, could not be separated by 
chromatography. The synthesis starts with diacylation of 1,3 propane-diol with two 
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equivalence of 2-phenyl pentenoic acid and DCC and DMAP followed by ring closing 
metathesis again by using Grubb’s 2nd generation catalyst. The two diastereomeric 
macrocycles 1-25 and 1-26 were separated by column chromatography (Scheme 1-4).   
 
 
 
Scheme 1-4. Synthesis of C7, C12  diphenyl [13]-macrodilactones 1-24 and 1-26. 
 
 
 Both trans diastereomer 1-25 and cis diastereomer 1-26 were crystalline solids 
that yielded to structural analysis from X-ray diffraction data. The structures of 1-25 and 
1-26 revealed the interplay between the key stereocenters and their shapes. Specifically, 
the relative (trans vs. cis) configuration of the phenyl groups at the α-stereogenic centers 
dictated the shape adopted by each diastereomer and the configuration dictated the planar 
chirality (Fig. 1-24). All four compounds differ in their topologies by virtue of either the 
differences in their planar chirality or their shape. 
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Fig. 1-24. Crystal structure of diastereomeric trans and cis [13]-macrodilactones, 1-25 
and 1-26  (1-25 /trans = 7R,12R,pS and 7S,12S,pR; 1-26 /cis = 7S,12R,pR and 7R,12S,pS). 
 
 The trans isomer was a racemic mixture of 7R,12R,pS-1-25 and 7S,12S,pR-1-25 
with its shape reminiscent of unsubstituted [13]-macrodilactones 1-19 and mono-
substituted [13]-macrodilactones 1-20 and 1-22. In fact, the RMSD between the 1-20 and 
7S,12S,pR-1-25  was only 0.0487. (Fig. 1-25a). This shape was adopted presumably 
because the two phenyl substituents were oriented outside of the ring and thus minimized 
transannular nonbonded interactions. The cis configured isomers of 1-26, on the other 
hand, adopted a different shape (RMSD 0.49 between 1-20 and 7S,12S,pR-26) (Fig. 1-
25b). Inspection of the top, or “triangle” views of 1-25 and 1-26  in Fig. 1-24 and 1-25 
illustrates the difference. The non-ribbon shape of 1-26  is more compressed, or kinked, 
relative to 1-25 and its molecular plane is also more twisted. While the diene precursor of 
1-26  was meso, 1-26  itself is a mixture of enantiomers defined by the planar chirality 
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(pS or pR) introduced to the molecules by cyclization. The relative stereochemistry at C7 
and C12 probably prevents formation of the ribbon shape because minimization of 
transannular interactions in this case requires reconfiguration of the backbone and hence 
a different shape. 
   
   
 
Fig. 1-25. Overlays of 1-20 in cyan and  (a) trans di-substituted  1-25 (b) cis di-
substituted 1-26 in yellow. 
 
 We previously observed that other key stereogenic centers (C2 and C4) can work 
constructively to reinforce the ribbon or against each other resulting in alternative shapes. 
For the C2, C4 compounds, the trans series adopted the ribbon conformation akin to 1-19, 
1-20, 1-22 and 1-25 whereas the cis series gave rise to a different macrocyclic shape that 
was coincidentally distinct from the shape of 1-26. The ribbon conformation seems to be 
of the lowest energy for these [13]-macrodilactones but, based on relative 
stereochemistry, alternative shapes and consequently topologies are available. Together 
the structural observations from this study suggest that shape and the topology of this 
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family of [13]-macrodilactones can be fine-tuned based on specific combinations of 
configuration on α-carbon stereogenic centers. 
 
1.8.2 Synthesis of di-substituted [13]-macrodilactones with C2, C7 and C2, C12 
substitution patterns  
 To explore some underlying general principles on the effect of combinations of 
two stereogenic centers and substitution pattern on the planar chirality, shape and overall 
topology of [13]-macrodilactones, we used the same synthetic route we have previously 
reported to synthesize new di-substituted macrocycles with new substitution patterns 
(Scheme 1-5). Compounds 1-27 and 1-28 have substituents at C2 and C12 while 
compounds 1-29 and 1-30 have substituents at C2 and C7. 1-27 and 1-28 were 
synthesized starting from 3-hydroxybutanol followed by acylation with 2-phenyl 
pentenoic acid and DCC and DMAP. The resulting mono-acylated hydroxybutanol was 
again acylated with, this time, pentenoic acid and DCC and DMAP. The last step is to 
close the ring, again, using Grubbs’ second-generation caltalyst. The two diastereomers 
1-27 and 1-28 (each a pair of enantiomers) were isolated using column chromatography. 
The same route was used to synthesize the diastereomers 1-29 and 1-30 but instead of 
using 2-phenyl pentenoic acid first followed by pentenoic acid, the sequential acylation 
with DCC and DMAP was reversed where pentenoic acid was used first to acylate the 3-
hydoxybutanol followed by another acylation with 2-phenyl pentenoic acid (Scheme 1-5).
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Scheme 1-5. Synthesis of C2, C7 and C7, C12 di-substituted [13]-macrodilactones. 
 
 Similar to the C7, C12 (compounds 1-25 and 1-26) and C2, C4 (compounds 1-31 
and 1-32) di-substituted [13]-macrodilactones, we isolated four stereosiomers with two 
different shapes for C2, C7 and C2, C12 di-substituted macrocycles (Fig. 1-26 and 1-27). 
The difference in planar chiralities, shape and overall topologies of all the di-substituted 
[13]-macrodilcatones are evident in both the 2D maps and the crystal structures (Fig. 1-
26 and 1-27). 
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Fig. 1-26. Structural properties of di-substituted [13]-macrodilactones with various 
substitution patterns and with pR planar chiralities as shown by the X-ray crystal 
structures and 2D maps.  
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Fig. 1-27. Structural properties of di-substituted [13]-macrodilactones with various 
substitution patterns and with pS planar chiralities as shown by the X-ray crystal 
structures and 2D maps.  
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1.8.3 Effect of relative cis/trans configuration of substitutents on the topology of di-
substituted 13-macrodilactones 
With respect to the contribution of combinations of stereogenic centers to the shape 
of the [13]-macrodilactone, we initially hypothesized that the relative (cis and trans) 
configuration dictates the shape of the macrocyle based on our observations on both C7, 
C12 (Figs. 1-26a, 1-27a) and C2, C4 (Figs. 1-26c, 1-27c) macrocycles. We define the cis/trans 
configuration in a similar manner to the designation of cis/trans configuration in 
cyclohexane. The trans isomers adopted the ribbon shape and the cis adapted the alternate 
shape. This trend held true for the C2, C12 macrocyle (Figs. 1-26c, 1-27c) but did not 
apply to C2, C7 macrocyle where the cis configured macrocycle adopted the ribbon shape 
and the trans adopted an alternate shape (Figs. 1-26d, 1-27d). Based on the crystal 
structures of the new di-substituted macrocycles we obtained, it is clear that it is not the 
relative cis/trans configuration that determines whether the di-substituted [13]-
macrodilactone will adopt th ribbon or the alternate shapes. 
 
1.8.4 Effect of substitution pattern on the topology of di-substituted [13]-
macrodilactones 
The alternative shape adopted by the di-substituted [13]-macrodilactone seemed to 
depend on the substitution pattern. Macrocyles 1-26 and 1-28 with substitutions at C7, 
C12 and C2, C12 respectively adopted a similar shape as shown by their crystal 
structures and 2D maps (Figs. 1-26a, 1-27a and Figs. 1-26c, 1-27c). Macrocyles 1-26 and 
1-28 have a five-atom alkene planar units instead of a four-atom planar units in the 
ribbon/triangular shape. Formation of a five-atom planar unit forced the alkene plane to 
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twist or deviate from the almost perpendicular orientation of the alkene plane (with 
respect to the molecular plane) in the ribbon/triangular shape. This deviation is clearly 
visualized through the positive migration of the alkene atoms in the 2D maps. Both 1-26 
and 1-28 have a substituent at C12 suggesting that the configuration or the geometry at 
C12 stereogenic center can greatly influence the shape of [13]-macrodilactones. More 
specifically, the type of shape where a five-atom alkene planar unit was formed instead of 
the typical four-atom alkene planar unit is probably controlled by the configuration at 
C12.  
Macrocycles 1-32 and 1-30 adopted yet another shape that is distinct from the 
ribbon/triangular shape and that of 1-26 and 1-28 as evident from their crystal structures 
and 2D maps (Figs. 1-26b, 1-27b and Figs. 1-26d, 1-27d). Pronounced difference can be 
seen in the orientation of the two carbonyl groups. The C=O groups in 1-32 and 1-30 are 
pointing in the same direction whereas in all the ribbon/triangular shape, the C=O groups 
are pointing in opposite direction. This orientation of carbonyl groups in 1-32 and 1-30 
probably forced the alkene plane to again deviate from the molecular plane. The 
deviation from the molecular plane is also clearly visualized through the negative 
migration of the alkene atoms (as opposed to the positive deviation seen for 1-26 and 1-
28) in the 2D maps. Both 1-32 and 1-30 have a substituent at C2 suggesting that, similar 
to C12, the configuration or the geometry at C2 stereogenic center can greatly influence 
the shape of [13]-macrodilactone. More specifically, the type of shape where the two 
carbonyls are pointing in the same direction is probably controlled by the configuration at 
C2.  
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1.8.5 Effect of the interplay between configurations at the stereogenic centers and 
stereogenic plane on topology of di-substituted [13]-macrodilactones 
 Inspection of the crystal structures to explore some underlying general principle 
that apply to all the di-substituted [13]-macrodilactones – with regard to the relationship 
of configurations at stereogenic centers, planar chirality and shape - revealed that the 
trend observed in mono-substituted macrocycles applies to the di-substituted [13]-
macrodilactones as well. For mono-substituted macrocycles, specific configuration at the 
stereogenic center (either R or S) resulted in only one planar chirality (either pS or pR). 
For C2 (and C4) streogenic center with methyl substituent, an R configuration should 
have a pR planar chirality while an S configuration should have a pS planar chirality. For 
the C7 (and C12) stereogenic center with phenyl substituent, it was the other way around. 
The R configuration should have a pS planar chirality while the S configuration should 
have a pR planar chirality (Table 2). As pointed out in the previous discussion, the 
appearance of the lack of correspondence between the general correlation of point and 
planar chirality for the C2-methyl and C7-phenyl mono-substituted macrocycles is due to 
the assignment of functional group prioritization based on CIP R and S designations. 
Specific geometry at the stereogenic center (point chirality) – driven by the preference for 
a pseudo-equatorial position – do indeed control the planar chirality. Similarly for the di-
substituted [13]-macrodilactones, if both configurations at the stereogenic centers agree 
with the point to planar chirality correspondence (Table 1-2) observed for the mono-
substituted [13]-macrodilactones – all of the substituents are in the pseudo-equatorial 
positions i.e. Figs. 1-26a – 7S, 12S pR; 1-26b – 2R, 4R, pR; 1-26c – 2R, 12S, pR; and 1-
26d – 2R, 7S, pR - the macrocycle adopts the most stable ‘ribbon’ shape. If on the other 
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hand, one of the stereogenic centers does not agree with the point to planar chirality 
correspondence – underlined stereogenic centers - (i.e. Fig. 1-26a - 7S, 12R, pR; 1-26b – 
2R, 4S, pR; 1-26c – 2R, 12R, pR; and 1-26d – 2S, 7S, pR), the macrocycle is forced to 
adopt a different or ‘alternate’ shape. For di-substituted [13]-macrodilactones, the proper 
configurations at the two stereogenic centers (point chiralities) and the olefenic 
stereogenic plane (planar chirality) is required to form the most stable conformation – the 
‘ribbon shape’ - while if one of the substituents at the stereogenic centers has an incorrect 
point to planar chirality correspondence, a different shape is adopted.  
 
1.8.6 Origin of the control of [13]-macrodilactone shape by two stereogenic centers 
We used a computational method once again to further explore the driving force 
behind the preference for ‘alternate’ shape conferred by the incorrect point-to-planar 
chirality correspondence in the stereogenic elements on the [13]-macrodilactones. Using 
the C7, C12 di-substituted [13]-macrodilactone as an example, we used ground-state 
energy minimization to look at the energy associated with the ‘ribbon’ shape (trans-7R, 
12R, pS) vs. the ‘alternate’ shape (cis-7R, 12S, pS) (Fig. 1-28). The ‘alternate’ shape is 
1.7 kcal/mol higher in energy than the ‘ribbon’ shape. Using the same combination of 
configurations at stereogenic centers and at the stereogenic plane that gave rise to a non-
ribbon shape (7R, 12S, pS) and forcing it to adopt a ribbon shape instead led to a 
conformation where one of the substituents is in pseudo-axial position (trans - 7R, 12R, 
pS). The specific combination 7R, 12S, pS adopted an alternate shape because adopting a 
ribbon shape is 2.4 kcal/mol higher in energy probably because of the transannular strain 
induced by a substituent in a pseudo-axial position. Similar to the mono-substituted 
 61 
macrocycle, it looks like it’s still the preference for pseudo-equatorial position that 
directs the type of shape adopted by the di-substituted [13]-macrodilactones. 
  
  
Fig. 1-28. Ground state energy minimization of C7, C12 disubstituted [13]-
macrodilactones 1-25. 
 
1.8.7 Conclusion: Rules of [13]-macrodilactone topology and its potential application 
to other macrocyclic systems 
 Our systematic approach in investigating the interplay between the planar units 
and the stereogenic elements (point chirality and planar chirality) to the overall structure 
of [13]-macrodilactones has provided some valuable insights that we thought would be 
helpful in synthesizing macrocyles with designed structural properties. Although our 
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observations are primarily based on X-ray crystallography data and some computational 
methods and are thus bound by the limitations inherent to these types of analyses, we 
believe that the fundamental information we learned from the [13]-macrodilactone 
systems has some value.  Below, we outlined the lessons we learned from this effort and 
discuss how it might be applicable to other ring systems with similar chemical 
composition.  
 
1) Unsubstituted [13]-macrodilactone adopts a single shape - a ‘ribbon’ shape when 
viewed from the side or a ‘triangular’ shape when viewed from the top of the 
molecular plane. This shape is rigidified by planar units alone. It exists as a pair of 
enantiomers brought about by stereogenic alkene plane. 
 For macrocycels that contain rigidifying planar units (macrolides, macrolactams, 
cyclic peptides or macrocycles with embedded alkene), there might be a preferred 
stable shape that is controlled by planar units alone. E-alkene containing macrocycles 
(without substituents) will most likely exist as a pair of planar enantiomers.     
  
2) There is a specific point-to-planar chirality correspondence when one stereogenic 
center is incorporated in [13]-macrodilactone regardless of the location and type of 
substituent. This means that a specific geometrical arrangement at a stereogenic 
center confers selectivity towards a specific planar chirality. If the substituent is 
considered to have the lowest priority based on CI specifications for assigning the 
configurations at stereogenic centers, the point-to-planar chirality correspondence is 
R to pR and S to pS. This selectivity is driven by the preference of the substituents to 
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be oriented away from the ring or in pseudo-equatorial position. Regardless of type 
and location of stereogenic center, [13]-macrodilactone with one substituent adopted 
the same ribbon shape.  
This observation implies that for E-alkene containing macrocyles, 
synthesizing macrocyles with a specific planar chirality (either pS or pR) is possible 
by incorporating a stereogenic center around the ring with a specific configuration 
(either R or S). For macrocycles that contain rigidifying planar units (macrolides, 
macrolactams, cyclic peptides or macrocycles with embedded alkene), changing the 
shape of macrocycles might not be possible by just incorporating one stereogenic 
center around the ring.  
 
3) All the di-substituted [13]-macrodilactone gave four different streoisomers with two 
different shapes (ribbon and various alternate shapes). A proper configuration -
controlled by the preference for pseudo-equatorial position - at both stereogenic 
centers and stereogenic plane is required to get the most stable ribbon shape. 
However, if one configuration at either setreogenic centers or the stereogenic plane 
do not match, an alternate shape is adopted which varies depending on the 
substitution pattern. 
In designing macrocycles with different shapes, at least two stereogenic 
centers might be needed to be incorporated in the ring. The most stable shape defined 
by the planar units alone is accessible only if all the substituents around the ring are in 
pseudo-equatorial position. If one of the substituents is in pseudo-axial position, an 
‘alternate’ shape will be adopted. Moreover, various ‘alternate’ shapes can be 
 64 
accessed depending on the substitution pattern. This observation we believe, will be 
very helpful for generating macrocyclic compound libraries with varied skeletons and 
for medicical chemists who are trying to optimze the biological and pharmacological 
profiles of bioactive macrocyles.     
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1.9 Experimental Section 
Experimental procedures and characterization of compounds in Chapter 1 
 
General 
Reactions were monitored using TLC. UV light, p-anisaldehyde, potassium 
permanganate (KMnO4) or ceric ammonium molybdate (CAM) solutions were used for 
visualization. Chromatography was performed on silica gel and solvent systems used 
were based on the Rf values. 1H NMR spectra (400 MHz ) were referenced to CDCl3 (δH 
7.27 ppm) and 13CNMR spectra (100 MHz) were referenced to CDCl3 (δC 77.23 ppm). 
 
Sequential Acylations 
Method  A: 
Dicyclohexylcarbodiimide (DCC) (1.09 mmol) and N,N-dimethylaminopyridine 
(DMAP) (0.3 mmol) in DCM (7 mL) were stirred at 0 °C. 4-pentenoic acid (1 mmol) was 
added and the mixture was stirred at the same temperature for 30 minutes until a white 
suspension was observed in the flask. 1,3-propanediol (1 mmol) in DCM (3 mL) was then 
added to the reaction mixture and stirred overnight at room temperature. The mixture was 
filtered through a celite and solvent was removed from the filtrate under reduced pressure. 
The crude residue was purified by silica gel column chromatography (3:1 Hex:EtOAc) to 
give the monoacylated product. 
Method B: 
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DCC (1.09 mmol) and DMAP (0.3 mmol) were added in DCM (40 mL) and cooled to 
0°C. The acid of choice (1 mmol) was added to the solution and stirred at the same 
temperature for 30 minutes. The monoacylated product (1 mmol) from the first acylation 
was then added to the mixture and stirred overnight at room temperature. The reaction 
mixture was filtered through celite and the solvent of the filtrate was removed under 
reduced pressure. Crude residue was purified by silica gel column chromatography to get 
the diene.  
 
One-pot acylation 
In a round bottom flask, DCC (0.23 g, 1.09 mmol) and DMAP (.037 g, 0.300 mmol) were 
dissolved in DCM (40mL), and the solution was cooled to 0°C. The acid of choice (1.00 
mmol) was added and stirred at the same temperature for 30 minutes. Either 1,3-
butanediol or 1,3-propanediol (0.500 mmol) in DCM (10 mL) was then added to the 
mixture and stirred overnight at room temperature. The mixture was then filtered through 
celite. The solvent of the filtrate was removed under reduced pressure and the residue 
was purified by silica gel column chromatography to get the diene. 
 
Ring Closing Metathesis 
Grubbs’ second-generation catalyst (0.050 mmol) was added to a solution of the diene (1 
mmol) in toluene (100 mL). The mixture was heated to reflux at 110 °C overnight. The 
toluene was removed under reduced pressure and the crude product was purified by 
column chromatography. 
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DMDO Epoxidation (Lee, D.; Sello, J. K.; Schreiber S. L. J. Am. Chem. Soc. 1999, 121, 
10648-10649) 
Excess amount of NaHCO3 (0.450 g, 0.94 mmol) and Oxone (0.450 g, 0.19 mmol) was 
added to a solution of  [13]-macrodilactone (racemic or chiral) (75 mg) in 
acetone:H2O:DCM (1:1:1, 15 mL) at 0 °C. The resulting heterogeneous mixture was 
stirred for 3 h at 0 °C and extracted with DCM. The epoxide was purified using column 
chromatography. 
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Characterization 
 
 
3-hydroxypropyl 4-pentenoate. The synthesis of this compound followed the general 
monoacylation procedure (Method A) to give 3-hydroxypropyl 4-pentenoate in 52% yield 
as a colorless oil (1.0 mmol scale). Rf 0.2 (30% EtOAc:Hex); 1HNMR (CDCl3) 400 MHz. 
δ 5.82 (ddd, 1H, J= 10.4, 6.3, 6.3, 6.3 Hz), 5.08 (dd, 1H, J = 16.6, 16.6, 0 Hz), 5.02 (dd, 
1H, J= 10.2, 10.2, 0 Hz), 4.25 (t, 2H, J = 6.1 Hz), 3.69 (m 2H), 2.80 (s, 1H), 2.41 (m, 4H), 
1.88 (qn, 2H, J = 6.1 Hz); 13C NMR (CDCl3) 100 MHz δ 173.6, 136.6, 115.6, 61.5, 59.0, 
33.6, 31.7, 28.9; TOF HRMS (DART) m/z calcd for C9H16O3 (M+H)+ 173.1099, found 
173.1191 
 
 
 
1-18. The synthesis of this compound can follow either the general procedure for 
synthesizing dienes (Method A and then Method B) or a one-pot acylation. The general 
route for dienes gave a better yield of (96%) in 26.0 mmol scale as colorless oil. Rf 0.58 
(20% EtOAc:Hex); 1HNMR (400 MHz, CDCl3) δ 5.83 (dddd/dq, 2H, J= 23.4, 6.4, 6.4, 
6.4), 5.04 (ddd, 4H, J= 24.7, 17.1, 1.3), 4.17 (ddd, 4H, J= 6.42, 6.42, 0), 2.42 (m, 8H), 
HO
O
O
O
O
O
O
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1.98 (dddd/tt, 2H, J= 6.3, 6.3, 6.3, 6.3); 13C NMR (100 MHz, CDCl3) δ 173.2, 136.8, 
115.8, 61.2, 33.7, 29.1, 28.2; TOF HRMS (DART) m/z calcd for C13H20O4 (M+H)+ 
241.1439, found 241.1425 
 
 
1-20. Followed the general RCM method to give the product in 54% yield and as a white 
crystalline solid (2.08 mmol scale). m.p. 61.2 – 61.7 °C; Rf 0.34 (20% EtOAc:Hex); 
1HNMR (400 MHz, CDCl3) δ 5.44 (m, 2H), 4.18 (ddd/dt, 4H, J= 5.7, 5.7, 0), 2.33 (m, 
8H), 2.02 (dddd/tt, 2H, J= 6.1, 6.1, 6.1, 6.1); 13C NMR (100 MHz, CDCl3) δ 173.9, 130.0, 
60.7, 34.4, 28.7, 26.1; TOF HRMS (DART) m/z calcd for C11H16O4 (M+H)+ 213.1127, 
found 213.1158 
 
 
rac-1-21. The synthesis of this compound followed the general method of dienes through 
monoacylation (Method B) in 50% yield and as a clear yellowish oil (0.63 mmol). Rf 0.6 
(20% EtOAc:Hex); 1HNMR (CDCl3) 400 MHz. δ 7.33 (m, 4H), 7.28 (m, 1H), 5.83 (m, 
1H), 5.74 (dddd/ddt, 1H, J= 17.0, 10.3, 6.7, 6.7), 5.08 (m, 2H), 5.01 (dd, 2H, J= 10.4, 
O
O
O
O
O
O
O
O
Ph
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5.0), 4.16 (ddd, 2H, J= 17.5, 11.34, 6.3), 4.08 (m, 2H), 3.66 (dd, 1H, J= 8.5, 7.1), 2.85 
(ddd, 1H, J= 14.8, 8.2, 8.2), 2.54 (ddd, 1H, J= 13.8, 6.8, 6.8), 2.39 (ddd, 4H, J= 15.5, 
11.35, 4.17), 1.93 (dddd/dq, 2H, J= 6.48, 6.48, 6.48, 6.48); 13C NMR (CDCl3) 100 MHz 
δ 173.5, 173.1, 138.7, 136.8, 135.4, 128.9, 128.1, 127.6, 117.3, 115.8, 61.5, 61.0, 51.7, 
37.7, 33.7, 29.1, 28.1; TOF HRMS (DART)m/z calcd for C19H24O4 (M+H)+ 317.1753, 
found 317.1732. 
 
S-1-21. Followed the general method of dienes through monoacylation (method A and 
then method B) in 75% yield as a yellowish oil (0.79 mmol). Rf 0.6 (20% EtOAc:Hex); 
[a]D +257.4° (c 1.0, CH2Cl2);1HNMR (CDCl3) 400 MHz. δ 7.30 (m, 5H), 5.80 (m, 2H), 
5.08 (m, 2H), 5.02 (dd, 2H, J=10.3, 4.9), 4.16 (ddd, 2H, J= 17.57, 11.09, 6.31), 4.07 (m, 
2H), 3.66(dd, 1H, J= 8.5, 7.0), 2.84 (ddd, 1H, J= 15.01, 8.07, 8.07), 2.54 (ddd, 1H, J= 
13.64, 6.74, 6.74), 2.38 (ddd, 4H, J= 14.71, 11.34, 4.35), 1.92 (dddd/dq, 2H, J= 6.37, 
6.37, 6.37, 6.37); 13C NMR (CDCl3) 100 MHz δ 173.5, 173.1, 138.7, 136.8, 135.4, 128.8, 
128.1, 127.6, 117.2, 115.7, 61.5, 61.0, 51.7, 37.6, 33.7, 29.0, 28.1; TOF HRMS (ESI) 
m/z calcd for C19H24O4 (M+Na)+ 339.1572, found 339.1556. 
O
O
O
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rac-1-22. Followed the general RCM method to give the product in 54% yield and as a 
white crystalline solid. m.p. 78-79 °C; Rf  0.4 (20% EtOAc:Hex); 1HNMR (CDCl3) 400 
MHz. δ 7.37 (d, 2H, J= 7.1), 7.31 (dd, 2H, J= 7.1, 7.1), 7.26 (dd, 1H, J= 3.1, 3.1), 5.55 
(m, 2H), 4.54 (m, 1H), 4.44 (m, 1H), 4.01 (ddd/dt, 1H, J= 8.2, 4.1, 4.1), 3.83 (ddd/dt, 1H, 
J= 8.2, 4.1, 4.1), 3.60 (dd, 1H, J= 12.6, 2.7), 2.77 (ddd/dt, 1H, J= 12.9, 12.0, 8.1), 2.35 
(m, 5H), 2.03 (m, 2H); 13C NMR (CDCl3) 100 MHz δ 174.2, 173.9, 139.1, 131.1, 129.1, 
128.9, 127.9, 127.6, 60.6, 60.4, 52.1, 37.9, 34.3, 28.8, 26.0; anal. for C17H20O4, C 70.78, 
H 6.96, O 22.26, found C 70.86, H 6.96.   
 
 
7S,pR-1-22. Followed the general method of RCM in 25% yield (scale) as a white solid. 
m.p. 72-74 °C; [a]D +2.6° (c 1.0, CH2Cl2); Rf  0.4 (20% EtOAc:Hex); 1HNMR (CDCl3) 
400 MHz. δ 7.39 (d, 2H, J= 7.2), 7.23 (dd, 2H, J= 7.2, 7.2), 7.26 (m, 1H), 5.56 (m, 2H), 
4.54 (m, 1H), 4.46 (m, 1H), 4.04 (ddd/dt, 1H, J= 8.4, 4.0, 4.0), 3.86 (ddd/dt, 1H, J= 8.4, 
4.0, 4.0), 3.62 (dd, 1H, J= 12.6, 2.9), 2.79 (ddd/dt, 1H, J= 12.9, 12.9, 8.2), 2.37 (m, 5H), 
O
O
O
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2.05 (m, 2H); ); 13C NMR (CDCl3) 100 MHz δ 174.1, 173.9, 139.0, 131.0, 129.0, 128.8, 
127.9, 127.6, 60.6, 60.4, 52.0, 37.9, 34.3, 28.7, 26.0; TOF HRMS (ESI) m/z calcd for 
C17H20O4 (M+Na)+ 311.1259, found 311.1253. 
 
 
rac-1-23. Compound rac-1-22 was epoxidized using a procedure for in situ generation of 
DMDO as described to give rac-1-23 in 64% yield (0.26 mmol) and as a white solid. m.p. 
100-102 °C; Rf  0.2 (20% EtOAc:Hex); 1HNMR (CDCl3) 400 MHz. δ 7.30 (m, 5H), 4.82 
(m, 2H), 3.91 (ddd/dt, 1H, J= 8.1, 3.7, 3.7), 3.72 (m, 2H), 2.87 (ddd, 2H, J= 8.8, 8.8, 2.6), 
2.47 (dd, 2H, J= 8.24, 5.04), 2.24 (m, 2H), 2.03 (m, 3H), 1.60 (m, 1H); 13C NMR 
(CDCl3) 100 MHz δ 173.4, 172.9, 139.1, 129.0, 127.7, 127.6, 60.2, 59.5, 58.5, 57.6, 47.8, 
36.7, 29.6, 26.9, 26.3; TOF HRMS (ESI) m/z calcd for C17H20O5 (M+Na)+ 327.1208, found 
327.1206. 
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7S,pR-1-23. Compound 7S,pR-1-22 was epoxidized using a procedure for in situ 
generation of DMDO as described to give 7S,pR-1-23 in 67% yield and as a white solid 
(0.25 mmol). mp 114-118 °C; [a]D +120.3° (c 1.0, CH2Cl2); Rf  0.2 (20% EtOAc:Hex); 
1HNMR (CDCl3) 400 MHz. δ 7.29 (m, 5H), 4.83 (m, 2H), 3.92 (ddd/dt, 1 H, J= 8.2, 4.3, 
4.3), 3.73 (m, 2H), 2.87 (ddd, 2H, J= 8.8, 8.8, 2.6), 2.47 (dd, 2H, J= 8.2, 5.3), 2.25 (m, 
2H), 2.06 (m, 2H), 2.00 (ddd/dt, 1H, J= 12.9, 9.6, 9.6), 1.61 (m, 1H); 13C NMR (CDCl3) 
100 MHz δ 173.4, 172.9, 139.1, 129.1, 127.7, 127.6, 60.2, 59.5, 58.5, 57.6, 47.8, 36.7, 
29.6, 26.9, 26.3; TOF HRMS (ESI) m/z calcd for C17H20O5 (M+Na)++ 327.1208, found 
327.1216. 
 
 
1-24. Followed the general procedure of diene through diacylation in 46% yield and clear 
yellowish oil (2.55 mmol). Rf 0.8 (20% EtOAc:Hex);  1HNMR (CDCl3) 400 MHz. δ 7.22 
(m, 10H), 5.63 (dddd/dt, 2H, J= 17.3, 10.3, 7.0, 7.0), 5.00 (dd, 2H, J= 17.1, 1.3), 4.92 (dd, 
2H, J= 10.2, 0), 3.96 (m, 4H), 3.54 (dd, 2H, J= 7.9, 7.9), 2.73 (ddd, 2H, J= 14.58, 8.05, 
8.05), 2.43 (ddd, 2H, J= 13.93, 6.75, 6.75), 1.77 (dddd/tt, 2H, J= 6.13, 6.13, 6.13, 6.13); 
13C NMR (CDCl3) 100 MHz δ 173.5, 138.7, 135.4, 128.9, 128.1, 127.6, 117.3, 61.3, 51.7, 
37.7, 28.1; TOF HRMS (ESI) m/z calcd for C25H28O4 (M+Na)++ 365.1753, found 365.1749. 
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1-25. Followed the general method of RCM in 47% yield (0.45 mmol) and as a white 
solid. m.p. 172-174 °C; Rf 0.56 (20% EtOAc:Hex); 1HNMR (CDCl3) 400 MHz. δ 7.33 
(m, 10H), 5.64 (ddd/dt, 2H, J= 3.67, 3.67, 0), 4.67 (m, 2H), 3.80 (ddd/dt, 2H, J= 7.09, 
3.17, 3.17), 3.62 (dd, 2H, J= 12.50, 2.14), 2.82 (m, 2H), 2.28 (dd, 2H, J= 12.62, 0), 2.03 
(m, 2H); 13C NMR (CDCl3) 100 MHz δ 174.1, 139.0, 130.3, 128.9, 127.8, 127.6, 59.7, 
51.8, 38.1, 25.5; TOF HRMS (DART) m/z calcd for C23H24O4 (M+H)+ 365.1753, found 
365.1749 
 
 
1-26. Followed the general method of RCM in 20% yield and as a white solid. m.p. 147-
156 °C; Rf 0.44 (20% EtOAc:Hex); 1HNMR (CDCl3) 400 MHz. δ 7.33 (m, 10 H), 5.74 
(ddd, 2H, J= 2.84, 2.84, 0), 4.41 (ddd, 2H, J= 11.37, 5.71, 5.71), 4.09 (ddd, 2H, J= 10.93, 
5.15, 5.15), 3.75 (ddd, 2H, J= 12.17, 3.31, 0), 2.78 (m, 2H), 2.40 (dd, 2H, J= 13.57, 0), 
2.08 (dddd/dq, 2H, J= 5.20, 5.20, 5.20, 5.20); 13C NMR (CDCl3) 100 MHz δ 174.1, 139.1, 
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129.7, 128.9, 128.1, 127.7, 63.1, 52.4, 36.9, 27.3; TOF HRMS (DART) m/z calcd for 
C23H24O4 (M+H)+ 365.1753, found 365.1748. 
 
 
diacylated diene precursor of 1-27 and 1-28. Followed the general method of dienes 
through monoacylation of 1,3 butanediol first with pentenoic acid to get the 
monoacylated 1,3 butanediol (method A) and then method B using 2-phenyl pentenoic 
acid  in 62% yield as a yellowish oil (0.8 mmol). Rf 0.8 (20% EtOAc:Hex); 1HNMR (400 
MHz, CDCl3) δ (m, 5H), 5.77 (m, 2H), 5.03 (m, 5H), 4.09 (m, 1H), 3.99 (ddd, 1H, J= 
11.4, 6.1, 6.1), 3.83 (ddd, 1H, J= 13.9, 7.8, 6.1), 3.63 (m, 1H), 2.83 (m, 1H), 2.54 (m, 1 
H), 2.39 (m, 1H), 2.34, (m, 2H), 1.83 (m, 2H), 1.25 (m, 2H), 1.15 (m, 3H); 13C NMR 
(100 MHz, CDCl3) δ 173.1, 138.9, 136.9, 135.5, 128.9, 128.0, 127.6, 117.1, 115.7, 68.5, 
60.7, 51.8, 37.6, 34.9, 33.6, 29.0, 20.3, 20.0; TOF HRMS (DART) m/z calcd for 
C23H26O4 (M+H)+ 331.1909, found 331.1921. 
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1-27. Obtained using the general RCM procedure in 21.2% yield (0.5 mmol) and as a 
white solid. m.p. 85.0 – 85.7 °C; Rf  0.48 (20% EtOAc:Hex); 1HNMR (400 MHz, CDCl3) 
δ 7.28 (m, 5H), 5.52 (m, 2H), 5.09 (ddd, 1H, J= 10.6, 6.1, 3.8), 4.34 (ddd, 1H, J= 12.1, 
12.1, 3.6), 3.94 (ddd, 1H, J= 11.2, 5.2, 2.2), 3.54 (ddd, 1H, J= 12.6, 2.5, 0), 2.79 (ddd, 1H, 
J= 13.0, 13.0, 9.3), 2.30 (m, 5H), 2.01 (m, 1H), 1.78 (m, 1H), 1.16 (dd, 3H, J= 6.24, 0); 
13C NMR (100 MHz, CDCl3) δ 174.1, 173.3, 139.1, 131.7, 129.12, 128.9, 127.6, 127.5, 
67.3, 60.5, 52.2, 37.6, 34.5, 33.5, 29.2, 20.5; TOF HRMS (DART) m/z calcd for 
C18H22O4 (M+H)+ 303.1596, found 303.1005 
 
 
 
1-28. Obtained using the general RCM procedure in 4.6% yield (0.5 mmol) and as a 
white solid. m.p. 96.3 – 96.9 °C; Rf  0.42 (20% EtOAc:Hex); 1HNMR (400 MHz, CDCl3) 
δ 7.30 (m, 5H), 5.60 (m, 2H), 5.12 (ddd, 1H, J= 9.9, 6.3, 3.7), 4.16 (m, 1H), 4.07 (m, 1H), 
3.83 (ddd, 1H, J= 11.7, 3.6, 0), 2.70 (ddd, 1H, J= 15.7, 11.7, 4.3), 2.39 (m, 5H), 1.96 
(dddd, 2H, J= 8.9, 8.9, 4.2, 4.2), 1.20 (dd, 3H, J= 6.4, 0); 13C NMR (100 MHz, CDCl3) δ 
174.2, 172.7, 139.4, 129.5, 128.9, 128.6, 128.0, 127.5, 69.4, 61.1, 52.2, 35.4, 34.0, 29.7, 
20.8; TOF HRMS (DART) m/z calcd for C18H22O4 (M+H)+ 303.1596, found 303.1606 
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3-hydroxybutyl 2-phenyl-4-pentenoate. The synthesis of this compound followed the 
general monoacylation procedure (Method A) to give 3-hydroxybutyl 2-phenyl-4-
pentenoate in 44% yield as a colorless oil (2.0 mmol scale). Rf 0.2 (30% EtOAc:Hex); 
1HNMR (CDCl3) 400 MHz δ 7.30 (m, 5H), 5.74 (ddt/dddd, 1H, J = 17.2, 10.5, 6.9, 6.9), 
5.09 (dd, 1H, J = 17.2, 0.0), 5.03 (dd, 1H, J = 10.3, 0), 4.34 (ddt/ dddd, 1H, J = 11.4, 8.4, 
5.0, 5.0), 4.13 (ddt/ dddd, 1H, J = 11.2, 7.7, 5.6, 5.6), 3.74 (m, 1H), 3.66 (dd, 1H, J = 8.7, 
6.9), 2.85 (ddd, 1H, J = 15.7, 8.5, 7.6), 2.54 (m, 1H), 2.19 (m, 1H), 1.71 (m, 2H), 1.16 
(dd, 3H, J= 6.0, 4.0); 13C NMR (CDCl3) 100 MHz δ 174.0, 135.4, 128.9, 128.1, 127.6, 
117.3, 65.1, 62.4, 62.3, 51.8, 38.2, 37.6, 23.6; TOF HRMS (DART) m/z calcd for 
C15H20O3 (M+H)+ 249.1491, found 249.1502 
 
 
 
diacylated diene precursor of 1-29 and 1-30. Followed the general method of dienes 
through monoacylation of 1,3 butanediol first with pentenoic acid to get the 
monoacylated 1,3 butanediol (method A) and then method B using 2-phenyl pentenoic 
acid  in 62% yield as a yellowish oil (0.8 mmol). Rf 0.6 (20% EtOAc:Hex); 1HNMR 
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(CDCl3) 400 MHz δ 7.26 (m, 5H), 5.72 (m, 2H), 5.00 (m, 5H), 4.09 (m, 2H), 3.62 (dd, 
1H, J= 8.3, 7.1), 2.82 (ddd, 1H, J = 14.8, 7.6, 7.6), 2.51 (ddd, 1H, J =13.9, 6.7, 6.7), 2.35 
(dd, 2H, J = 2.5, 0), 2.33 (dd, 2H, J = 2.6, 0.0), 2.20 (m, 2H), 1.17 (dd, 3H, J = 8.5, 6.5); 
13C NMR (CDCl3) 100 MHz δ 173.4, 172.4, 138.6, 136.7, 135.3, 128.7, 128.0, 127.4, 
117.1, 115.6, 67.9, 61.3, 51.6, 37.5, 34.8, 33.8, 29.0, 20.1; TOF HRMS (DART) m/z 
calcd for C20H26O4 (M+H)+ 331.1409, found 331.1920. 
 
 
1-29. Obtained using the general RCM procedure in 13% yield (0.5 scale) and as a white 
solid. m.p. 112-113 °C; Rf 0.52 (20% EtOAc:Hex); 1HNMR (CDCl3) 400 MHz δ 7.30 (m, 
5H), 5.52 (ddd/dt, 2H), J = 8.8, 4.8, 4.8), 5.12 (m, 1H), 4.39 (ddd, 1H, J= 14.9, 11.1, 3.6), 
3.76 (ddd, 1H, J = 11.1, 5.7, 1.4), 3.54 (ddd, 1H, J= 12.5, 2.6, 0.0), 2.74 (ddd, 1H, J = 
13.0, 13.0, 9.1), 2.41 (m, 2H), 2.27 (m, 3H), 2.02 (m, 1H), 1.75 (m, 1H), 1.29 (dd, 3H, J 
= 6.2, 0); 13C NMR (CDCl3) 100 MHz δ 174.4, 172.9, 139.0, 130.9, 129.7, 128.8, 127.9, 
127.6, 66.8, 60.5, 52.1, 38.3, 34.3, 33.5, 28.2, 20.7; TOF HRMS (DART) m/z calcd for 
C18H22O4 (M+H)+ 303.1596, found 303.1594 
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1-30. Obtained using the general RCM procedure in 17% yield (0.5 mmol) and as a white 
solid. m.p. 75 °C; Rf 0.47 (20% EtOAc:Hex); 1HNMR (CDCl3) 400 MHz δ 7.31(m, 5H), 
5.65 (ddd/dt, 2H, J = 5.9, 5.9, 5.9), 5.13 (m, 1H), 4.33 (ddd, 1H, J = 11.6, 6.8, 3.4), 3.70 
(ddd, 1H, J = 0, 3.7, 11.6), 2.68(m, 1H), 2.41 (m, 4H), 2.26 (m, 1H), 1.96 (m, 2H), 1.28 
(dd, 3H, J = 6.2, 0.0); 13C NMR (CDCl3) 100 MHz δ 174.1, 173.4, 139.1, 130.9, 129.2, 
128.9, 128.3, 127.5, 70.1, 62.7, 52.7, 36.7, 35.0, 34.3, 27.5, 20.9; TOF HRMS (DART) 
m/z calcd for C18H22O4 (M+H)+ 303.1596, found 303.1637 
 
X-ray Crystallography Data 
 
Procedure for determination of RMSDs  
The root mean square deviations (RMSDs) were produced with the structure overlay 
feature of the Mercury software package. Pairs of atoms were selected to calculate the 
square root of the mean square differences between atomic coordinates. Our approach 
focused on the 13 atoms of the macrocycle in compound 1. These coordinates were 
mapped onto the corresponding atom positions of compounds 4, 6, and 7. All of the 
compounds reported here crystallized as racemic mixtures. The coordinates were 
carefully inspected to insure the average RMSD between two sets of coordinates reflected 
corresponding conformations in the alkene and ester functional groups.  
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 X-ray Crystallography Data 
 
Procedure for determination of RMSDs  
The root mean square deviations (RMSDs) were produced with the structure overlay 
feature of the Mercury software package. Pairs of atoms were selected to calculate the 
square root of the mean square differences between atomic coordinates. Our approach 
focused on the 13 atoms of the macrocycle in compound 1-20. These coordinates were 
mapped onto the corresponding atom positions of compounds 1-22, 1-25, and 1-26. All of 
the compounds reported here crystallized as racemic mixtures. The coordinates were 
carefully inspected to insure the average RMSD between two sets of coordinates reflected 
corresponding conformations in the alkene and ester functional groups.  
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Fig. 1-29 A thermal ellipsoid plot of 1-19 (spider-15025) at a 50% probability level. The 
full numbering scheme is shown.  Hydrogen atoms are depicted as spheres.
 82 
 Table 1-3.  Crystal data and structure refinement for 1-19 (spider-15025). 
 
Identification code  spider-15025 
Empirical formula  C11H16O4 
Formula weight  212.24 
Temperature  93(2) K 
Wavelength  0.71075 Å 
Crystal system  Monoclinic 
Space group  P 21/c 
Unit cell dimensions a = 12.9215(9) Å α = 90°. 
 b = 9.3726(2) Å β = 91.858(6)°. 
 c = 8.9925(2) Å γ = 90°. 
Volume 1088.49(8) Å3 
Z 4 
Density (calculated) 1.295 Mg/m3 
Absorption coefficient 0.098 mm-1 
F(000) 456 
Crystal size 0.410 x 0.380 x 0.260 mm3 
Crystal color and habit Colorless Block 
Diffractometer Rigaku R-AXIS RAPID imaging plate 
Θ range for data collection 3.140 to 27.474°. 
Index ranges -16 ≤ h ≤ 16, -12 ≤ k ≤ 12, -11 ≤ l ≤ 11 
Reflections collected 42983 
Independent reflections 2492 [R(int) = 0.0300] 
Observed reflections (I > 2σ(I)) 2255 
Completeness to θ = 25.242° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.945 
Solution method SHELXS-2013 (Sheldrick, 2013) 
Refinement method SHELXL-2014/7 (Sheldrick, 2014) 
Data / restraints / parameters 2492 / 0 / 136 
Goodness-of-fit on F2 1.071 
Final R indices [I>2σ(I)] R1 = 0.0320, wR2 = 0.0807 
R indices (all data) R1 = 0.0349, wR2 = 0.0823 
Largest diff. peak and hole 0.311 and -0.174 e.Å-3 
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Fig. 1-30 A thermal ellipsoid plot of rac-1-22 (spider-15025) at a 50% probability level. 
The full numbering scheme is shown.  Hydrogen atoms are depicted as spheres. 
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Table 1-4.  Crystal data and structure refinement for compound 1-22. 
 
Identification code  compound 4 
Empirical formula  C17H20O4 
Formula weight  288.33 
Temperature  93(2) K 
Wavelength  1.54187 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 5.51640(10) Å α = 94.989(7)° 
 b = 11.8803(3) Å β = 90.739(6)° 
 c = 23.3669(16) Å g = 98.520(7)° 
Volume 1508.23(12) Å3 
Z 4 
Density (calculated) 1.270 Mg/m3 
Absorption coefficient 0.731 mm-1 
F(000) 616 
Crystal color Colorless 
Crystal size 0.200 x 0.200 x 0.050 mm3 
Θ range for data collection 1.899 to 68.240° 
Index ranges -6  ≤  h  ≤  6, -14  ≤  k  ≤  14, -28  ≤  l  ≤  28 
Reflections collected 54047 
Independent reflections 5407 [R(int) = 0.0459] 
Completeness to θ = 67.687° 98.3 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.964 and 0.802 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5407 / 0 / 379 
Goodness-of-fit on F2 1.054 
Final R indices [I>2σ(I) = 4987 data] R1 = 0.0391, wR2 = 0.0948 
R indices (all data) R1 = 0.0421, wR2 = 0.0973 
Largest diff. peak and hole 0.446 and -0.216 e.Å-3 
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Figure 1-31. A thermal ellipsoid plot of 1-25 at a 50% probability level. The full 
numbering scheme is shown.  Hydrogen atoms are depicted as spheres. 
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Table 1-5.  Crystal data and structure refinement for compound 1-25. 
 
Identification code  compound 6 
Empirical formula  C23H24O4 
Formula weight  364.42 
Temperature  150(2) K 
Wavelength  0.71075 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 5.5848(4) Å α = 69.615(5)°. 
 b = 11.7915(8) Å β = 84.229(6)°. 
 c = 15.6064(11) Å g = 81.837(6)°. 
Volume 952.16(12) Å3 
Z 2 
Density (calculated) 1.271 Mg/m3 
Absorption coefficient 0.086 mm-1 
F(000) 388 
Crystal color Colorless 
Crystal size 0.220 x 0.210 x 0.190 mm3 
Theta range for data collection 3.494 to 27.468° 
Index ranges -7  ≤  h  ≤  7, -15  ≤  k  ≤  15, -20  ≤  l  ≤  20 
Reflections collected 16756 
Independent reflections 4345 [R(int) = 0.0758] 
Completeness to theta = 25.242° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.984 and 0.795 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4345 / 0 / 245 
Goodness-of-fit on F2 1.092 
Final R indices [I>2sigma(I) = 2226 data] R1 = 0.0510, wR2 = 0.1119 
R indices (all data, ? Å) R1 = 0.1232, wR2 = 0.1695 
Extinction coefficient 0.033(5) 
Largest diff. peak and hole 0.294 and -0.298 e.Å-3 
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Figure 1-32. A thermal ellipsoid plot of 1-26 at a 50% probability level. The full 
numbering scheme is shown.  Hydrogen atoms are depicted as spheres. 
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Table 1-6.  Crystal data and structure refinement for compound 1-26. 
 
Identification code  compound 7 
Empirical formula  C23H24O4 
Formula weight  364.42 
Temperature  93(2) K 
Wavelength  1.54187 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 5.59160(10) Å α = 70.326(5)°. 
 b = 11.9281(2) Å β = 80.097(6)°. 
 c = 15.3677(11) Å g = 79.031(6)°. 
Volume 941.04(8) Å3 
Z 2 
Density (calculated) 1.286 Mg/m3 
Absorption coefficient 0.701 mm-1 
F(000) 388 
Crystal color Colorless 
Crystal size 0.270 x 0.140 x 0.050 mm3 
Θ range for data collection 3.075 to 66.499° 
Index ranges -6 ≤ h  ≤  6, -14  ≤  k  ≤  14, -18  ≤  l  ≤  18 
Reflections collected 28626 
Independent reflections 3254 [R(int) = 0.0430] 
Completeness to θ = 66.499 ° 97.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.966 and 0.850 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3254 / 0 / 244 
Goodness-of-fit on F2 1.073 
Final R indices [I>2σ(I) = 3006 data] R1 = 0.0294, wR2 = 0.0735 
R indices (all data) R1 = 0.0317, wR2 = 0.0749 
Largest diff. peak and hole 0.208 and -0.153 e.Å-3 
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Figure 1-33. A thermal ellipsoid plot of 1-27 (spider_13084) at a 50% probability level.  
The hydrogen atoms are shown as spheres.  
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Table 1-7.  Crystal data and structure refinement for compound 1-27 (spider_13084). 
 
Identification code  spider_13084 
Empirical formula  C18H22O4 
Formula weight  302.35 
Temperature  150(2) K 
Wavelength  0.71075 Å 
Crystal system  Orthorhombic 
Space group  P b c a 
Unit cell dimensions a = 8.9681(3) Å a = 90° 
 b = 9.8245(3) Å b = 90° 
 c = 36.663(3) Å g = 90° 
Volume 3230.3(3) Å3 
Z 8 
Density (calculated) 1.243 Mg/m3 
Absorption coefficient 0.087 mm-1 
F(000) 1296 
Crystal color Colorless 
Crystal size 0.220 x 0.200 x 0.190 mm3 
Θ range for data collection 3.125 to 27.483° 
Index ranges -11 ≤ h ≤ 11, -12 ≤ k ≤ 12, -47 ≤  l ≤ 47 
Reflections collected 98785 
Independent reflections 3708 [R(int) = 0.0762] 
Completeness to θ = 25.242° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.984 and 0.849 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3708 / 0 / 290 
Goodness-of-fit on F2 1.057 
Final R indices [I>2σ(I) = 2883 data] R1 = 0.0483, wR2 = 0.1037 
R indices (all data) R1 = 0.0674, wR2 = 0.1120 
Largest diff. peak and hole 0.149 and -0.190 e.Å-3 
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Figure 1-34. A thermal ellipsoid plot of 1-28 (007-15017) at a 50% probability level.  
The hydrogen atoms are shown as spheres. The chirality of atom C2 is R; C12 is R. 
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Table 1-8.  Crystal data and structure refinement for 1-28 (007-15017). 
 
Identification code  007-15017 
Empirical formula  C18H22O4 
Formula weight  302.35 
Temperature  93(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  C 2/c 
Unit cell dimensions a = 17.6902(12) Å α = 90°. 
 b = 5.6442(4) Å β = 103.867(2)°. 
 c = 32.347(2) Å γ = 90°. 
Volume 3135.6(4) Å3 
Z 8 
Density (calculated) 1.281 Mg/m3 
Absorption coefficient 0.727 mm-1 
F(000) 1296 
Crystal size 0.200 x 0.200 x 0.090 mm3 
Crystal color and habit Colorless Prism 
Diffractometer Rigaku Saturn 944+ CCD 
Θ range for data collection 2.814 to 67.878°. 
Index ranges -20 ≤ h ≤ 21, -6 ≤ k ≤ 6, -38 ≤ l ≤ 38 
Reflections collected 47305 
Independent reflections 2825 [R(int) = 0.0476] 
Observed reflections (I > 2σ(I)) 2574 
Completeness to θ = 67.679° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.937 and 0.768 
Solution method SHELXT-2014/5 (Sheldrick, 2014) 
Refinement method SHELXL-2014/7 (Sheldrick, 2014) 
Data / restraints / parameters 2825 / 0 / 200 
Goodness-of-fit on F2 1.052 
Final R indices [I>2σ(I)] R1 = 0.0282, wR2 = 0.0690 
R indices (all data) R1 = 0.0318, wR2 = 0.0707 
Largest diff. peak and hole 0.192 and -0.197 e.Å-3 
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Figure 1-35. Thermal ellipsoid plot and the full numbering scheme of 1-29 (007-15060). 
All atoms shown are depicted with 50% thermal contours. The hydrogen atoms are 
shown as spheres. The chirality of atom C2 is S; C12 is S. 
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Table 1-9.  Crystal data and structure refinement for 1-29 (007-15060). 
 
Identification code  007-15060 
Empirical formula  C18H22O4 
Formula weight  302.35 
Temperature  93(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P 21/c 
Unit cell dimensions a = 12.8744(9) Å α = 90°. 
 b = 13.5401(9) Å β = 104.358(4)°. 
 c = 9.4132(7) Å γ = 90°. 
Volume 1589.7(2) Å3 
Z 4 
Density (calculated) 1.263 Mg/m3 
Absorption coefficient 0.717 mm-1 
F(000) 648 
Crystal size 0.200 x 0.200 x 0.090 mm3 
Crystal color and habit Colorless Prism 
Diffractometer Rigaku Saturn 944+ CCD 
Θ range for data collection 3.544 to 66.580°. 
Index ranges -15 ≤ h ≤ 15, -15 ≤ k ≤ 15, -11 ≤ l ≤ 11 
Reflections collected 49323 
Independent reflections 2784 [R(int) = 0.0879] 
Observed reflections (I > 2σ(I)) 2355 
Completeness to θ = 66.580° 98.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.938 and 0.684 
Solution method SHELXT-2014/5 (Sheldrick, 2014) 
Refinement method SHELXL-2014/7 (Sheldrick, 2014) 
Data / restraints / parameters 2784 / 0 / 200 
Goodness-of-fit on F2 1.049 
Final R indices [I>2σ(I)] R1 = 0.0356, wR2 = 0.0934 
R indices (all data) R1 = 0.0440, wR2 = 0.1008 
Largest diff. peak and hole 0.230 and -0.266 e.Å-3 
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Figure 1-36. Thermal ellipsoid plot of 1-30 (007_13099). All atoms shown are depicted 
with 50% thermal contours. The hydrogen atoms are shown as spheres.  
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Table 1-10.  Crystal data and structure refinement for 1-30 (007_13099). 
 
Identification code  007_13099 
Empirical formula  C18H22O4 
Formula weight  302.35 
Temperature  93(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P 21/c 
Unit cell dimensions a = 12.2539(10) Å a = 90° 
 b = 5.61320(10) Å b = 103.473(8)° 
 c = 23.7795(4) Å g = 90° 
Volume 1590.63(15) Å3 
Z 4 
Density (calculated) 1.263 Mg/m3 
Absorption coefficient 0.716 mm-1 
F(000) 648 
Crystal color Colorless 
Crystal size 0.220 x 0.110 x 0.090 mm3 
Θ range for data collection 3.709 to 65.048° 
Index ranges -14 ≤ h ≤ 14, -6 ≤ k ≤ 6, -24 ≤ l ≤ 27 
Reflections collected 24316 
Independent reflections 2673 [R(int) = 0.0447] 
Completeness to θ = 65.048° 98.2 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.938 and 0.818 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2673 / 0 / 200 
Goodness-of-fit on F2 1.027 
Final R indices [I>2σ(I) = 2490 data] R1 = 0.0316, wR2 = 0.0848 
R indices (all data) R1 = 0.0344, wR2 = 0.0890 
Largest diff. peak and hole 0.200 and -0.173 e.Å-3 
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Computational details for energy minization experiments  
 
Quantum chemical calculations were performed using Gaussian 09. Geometry 
optimization and vibrational frequency calculations in the gas phase were carried out at 
the M06-2x/6-31+g(d) level of theory. The M06-2x functional was selected over other 
popular density functionals due to its adequate description of noncovalent interactions in 
macrocycles. Stationary points were characterized by frequency calculations at 298 K, 
with structures at energy minima showing no negative frequencies and transition-states 
showing one negative frequency. All energy values are zero point corrected and shown 
are in kcal mol-1, bond lengths are reported in Ångstroms (Å), and bond angles in degrees 
(˚). Molecular figures were generated using CYLView. 
 
Computational experiments designed to determine the effect of the configuration at the 
stereogenic center to the preference for a specific planar chirality of monosubstituted 
[13]-mcrodilacone. 
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Chapter 2 
 
A cardiac glycoside activities link Na+/K+ ATPase ion-transport to breast cancer 
migration via correlative SAR 
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2.1 Introduction to cell migration 
 In its simplest definition, cell migration refers to the translation of the whole cell 
body from one location to another1.  It is a highly complex and dynamic process that is 
tightly regulated and coordinated spatially and temporally. In general, migration begins 
when a cell responds to an external signal to migrate through polarization or formation of 
distinct front and rear part. The front part forms a protrusion in the direction of migration, 
which is then attached to the substratum by adhesion molecules. At the leading edge of 
this protrusion, actin polymerization generates contraction forces, which move the cell 
forward. At the rear, actin depolymerization retracts the cell and adhesion molecules 
detach the rear portion from the substratum. The specific details (mechanics, mechanisms 
and regulation) of each of these processes comprise a huge current research field.  
 Cell migration is a fundamental cellular process that is critical for a number of 
physiological and pathological phenomena such as wound healing2, tissue remodeling, 
angiogenesis, and cancer metastasis3. Because of the highly complex nature of the 
choreography, mechanics and regulation of cell migration, no complete model that 
incorporates all of its components currently exists. One of the major problems in 
determining the precise roles of each of the proteins involved in cell migration is the lack 
of potent and selective inhibitors for the functions of these proteins. Besides their 
therapeutic potential, small-molecule inhibitors of cell migration serve as valuable tools 
to probe the molecular basis of cell motility4.  
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2.2. Small molecule inhibitors of cell migration 
 Most of the reported small molecule inhibitors of cell migration (Fig. 2-1) target 
the two major parts of cell migration machinery, the microtubule and actin. Some of the 
small molecules that inhibit cell migration by affecting the microtubule include 
colchicine, which inhibits tubulin polymerization and destabilizes the microtubule5 and 
taxol, which, in contrast to colchicine, is a microtubule-stabilizing agent6. Those that 
modulate actin functions can be superficially classified as (1) actin-filament destabilizers 
(2) actin filament-stabilizers and (3) inhibitors of actin-binding and actin-regulatory 
proteins4. Examples of actin-filament destabilizers include cytochalasin B, cytochalasin 
D and latrunculin A. Cytochalsin is the most highly characterized microtubule 
destabilizer which acts by binding and blocking the end of actin filaments and thus 
inhibiting dynamics at this end of the filament7. Among actin filament-stabilizer, the most 
popular is phalloidin, a phallotoxin from a poisonous mushroom. Phalloidin, although not 
cell penetrable, is a very useful probe molecule commonly conjugated to a fluorophore 
and used for visualizing F-actin7. Jasplakinolide, on the other hand, is a cell-permeable 
actin-stabilizer8.  
 In contrast to the vast number of small molecules that affect cell migration by 
modulating the activities of actin and microtubules, there are only very few that targets 
actin-binding proteins and actin-regulatory proteins and thus new small molecules that 
target these proteins will be valuable for understanding the regulatory mechanism of actin 
dynamics. Some examples include blebistatin  (an inhibitor of class II-skeletal muscle 
myosin)9, synthetic naphthalenesulfonamide, ML-9 (inhibitor of myosin light chain 
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kinase)10 and synthetic pyridine derivative Y-27632, an inhibitor of Rho-associated 
kinase11.  
 There are also a few cell migration inhibitors whose target is unknown. One 
example is the 15-membered macrocyclic natural product Motuporamine C extracted 
from a marine sponge Xestospongia exigua12. It was found to inhibit tumor cell invasion 
and angiogenesis13. Finding the biomolecular target of cell migration inhibitors could 
contribute to the complete understanding of cell migration. The small molecules 
previously discussed exemplify mechanisms of actions that have already been identified. 
With the advances in screening technologies as well as small molecule library generation, 
more useful probes are expected to be discovered and will continue to push the boundary 
of knowledge in the field of cell migration. Please refer to an excellent review article4 for 
a more thorough discussion of cell migration inhibitors.  
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Fig. 2-1. Representative small molecule inhibitors of cell migration. 
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2.3 Chemical genetics screening for cell sheet migration using a HTS scratch-wound 
assay 
 Collective cell migration, although less studied than individual cell migration, is 
the mode of migration that is operative in physiological processes such as wound healing, 
gastrulation, tissue repair and cancer metastasis14. Single cells must abandon their 
individual migratory behavior and coordinate their cytoskeletal activities with adjacent 
cells across cell-cell junctions in order to migrate collectively as a cell sheet. Assays that 
can recapitulate this mode of migration constitute valuable methods for understanding the 
fundamental mechanisms and mechanics of collective cell migration.   
 Cultured epithelial cells provide a great model system for understanding 
collective cell migration as well as interactions of cells in a sheet. Scratching the 
monolayer of epithelial cells creates a gap or ‘wound’ that can initiate the migration of 
cells towards the wound; this is the process of wound closure (Fig. 2-2). Movement of the 
cell sheet during wound closure in cultured epithelial cells is very similar to cell sheet 
movement in vivo during the re-epithelialization step of wound healing and during 
embryonic morphogenesis of various organisms15. Madin-Darby canine kidney (MDCK) 
cells are one of the widely used cell line for investigating collective cell migration using 
the wound-closure or scratch-wound assay. MDCK cells move as a cohesive and 
coherent sheet of cells without loss of cell-cell contact with multiple rows of cells 
actively contributing to cell sheet movement through protrusive cell crawling16. 
 The Fenteany lab adapted the MDCK cell scratch-wound assay to a high-
throughput format and used this for chemical genetic screening of epithelial cell sheet 
migration inhibitors17. The ‘quantitative’ version of scratch-wound assay begins with 
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addition of either a test compound or a DMSO control in a confluent monolayer of 
MDCK cells. Mechanical wounding of the monolayer (using a pipette tip) introduces a 
circular wound, which triggers the collective cell migration of the epithelial sheet (Fig. 2-
2). The rate of collective cell sheet migration is measured by quantifying the progress of 
wound-closure, which in turn is monitored by taking pictures of each well at different 
time points. The remaining open area at each time-point is calculated by tracing the 
wound margin in each image using the ImageJ software. For high-throughput screening, 
an ‘end-point’ version of the scratch-wound assay is done. In this version, the test 
compounds are only assayed at one concentration and the compound is considered active 
if the wound area is still open at a time point when the DMSO-treated well is already 
closed. To verify and carefully characterize the antimigratory activity of the active 
compounds, the previously described quantitative wound-closure assay is used where 
multiple concentrations of active compounds are assayed to generate a dose-response 
curve, % inhibition and IC50 values. 
 
 
 
 
 
 
 
 
  
 
Fig. 2-2. Scratch-wound assay of  DX-52-1. The figure was re-used with permission. 
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 Using this strategy, the Fenteany lab discovered new small molecule inhibitors of 
epithelial cell sheet migration with new protein targets and mechanisms of actions. Some 
of the small molecules discovered using this strategy include the small molecule DX-52 
and locostatin (Fig. 2-3). DX-52 is an analog of the natural product quinocarmycin that 
targets radixin and inhibited the epithelial cell sheet migration by disrupting the 
interaction of radixin and actin16. This small molecule helped clarify the role of radixin in 
epithelial cell sheet migration where G protein-coupled receptor kinase 2 (GRK2) was 
found to activate radixin leading to the regulation of membrane protrusion in migrating 
epithelial cells18. Locostatin on the other hand, targets RKIP and inhibited the cell 
migration by disrupting the RKIP-Raf 1 interaction19. Locostatin has been a valuable 
probe molecule in understanding the role of RKIP in epithelial and cancer cell migration, 
invasion and metastasis20. 
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Fig. 2-3. Representative epithelial cell sheet migration small molecule probe 
discovered through high throughput scratch-wound assay in MDCK cells. 
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2.4 Chemical genetics screening for breast cancer cell migration 
 The same high-throughput scratch-wound assay was adapted to a 96-well plate 
format to screen compound libraries for inhibitors of triple-negative breast cancer cell 
migration. Triple negative cells are a type of breast cancer that is refractory to current 
chemotherapeutic options. Instead of MDCK cells, immortalized triple negative breast 
cancer cell lines (BT20 and MDA-MB-231) were used to screen three compound libraries. 
The first library screened was a small collection of [13]-macrodilactones and 
carbohydrate-fused [13]-macrodilcatones synthesized in the Peczuh Lab. The next 
compound libraries screened were commercial chemical libraries of natural product (880 
compounds) and synthetic small molecules (12,720 compounds) from the companies 
Analyticon and Chembridge respectively. The screening strategy starts at 50 µM 
concentration. Active compounds at this concentration are then cherry-picked and 
rescreened at lower concentrations (Table 2-1). New small molecule probes for cell 
migration were discovered from this screening effort, which could potentially be 
followed up for further SAR, target ID and mechanism of action studies. The next 
paragraphs will briefly describe the results of these screening efforts. The full list and 
structure of small molecule ‘hits’ from the Analyticon natural product library can be 
found in the Appendix. 
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Table 2-1. Screening of three compound libraries for MDA-MB-231 breast cancer cell 
migration inhibitors  
 
Concen-
tration 
PZ  library (9 
compounds) 
Natural product  
(880 compounds) 
Synthetic small molecules  
(12,720 compounds) 
50 µM (3) (55) 6 % 1,232 10 % 
10 µM  (13) 1.5 % 43 0.4 % 
2 µM  (10) 1.1 % 28 0.2 % 
400 nM  (6) 0.7 % 19 0.1 % 
80 nM  (6) 0.7 % 0 0 % 
 
2.4.1 Results and discussion for screening of [13]-macrodilactone library 
 The triple negative breast cancer cell line BT20 was used to screen the small 
macrocyle library from the Peczuh Lab. In this effort, an octylglucoside-fused [13]-
macrodilactones 2-1, 2-2 and 2-3 (Fig. 2-4) were found to inhibit the migration of this 
cell line at 30-50 µM concentrations. An SAR study was done to further characterize 
their antimigratory activity. The full details of this project can be found in the published 
report21. This section of this thesis chapter will only summarize the important results and 
include one new interpretation for the SAR data in light of the new insights learned from 
the first chapter.  
 The active compounds 2-1, 2-2 and 2-3 (Table 2-2) discovered from the initial 
qualitative scratch-wound assay were eventually found to have a low therapeutic index. 
Therapeutic index is the ratio of MLC (maximum lethal concentration) to MIC (minimum 
inhibitory concentration) when assayed using the quantitative scratch-wound assay and 
thus prevented the determination of IC50 values. We hypothesized that the low 
therapeutic index is due to the cytostatic or cytotoxic activities of these compounds. To 
test this hypothesis, the compounds were evaluated in a cell viability assay using the cell-
counting kit 8 (CCK8) – a highly water soluble tetrazolium salt. The intermediate 
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molecules (synthetic precursors) 2-5, 2-6 and 2-7 during the synthesis of the 
octylglucoside-fused [13]-macrodilactones were also evaluated for their antiproliferative 
and cytotoxic activities (Table 2-2).  
 
 
 
 
 
 
 
 
 
 
        
 
 
 
 
 
 
Table 2-2. SAR in cell viability assay 
 
Compound MIC  (µM) 
IC50  
(µM) 
95% CI  
(µM) 
MLC  
(µM) 
Therapeutic 
Index  
(MLC/MIC) 
2-1 10 85.1 82.8 – 87.4 300 30 
2-2 50 91.4 89.2 – 93.6 300 6 
2-3 50 107 102.6 – 111.5 > 300 6 
2-4 10 38.1 37.3 – 38.8 50 5 
2-5 25 52.9 51.2 – 53.8 75 3 
2-6 25 61.1 60.1 – 60.2 100 4 
2-7 10 47.1 43.8 – 50.1 75 7.5 
 
Fig. 2-4. Representative carbohydrate-fused [13]-macrodilactones and synthetic 
precursors tested for cell viability assay. The top compounds are octylglucoside-fused 
[13]-macrodilactones while the bottoms ones are some of the intermediate molecules 
during the synthesis. Compounds 2-1, 2-2 and 2-3 were the octylglucoside-fused [13]-
macrodilactones active at the qualitative scratch-wound assays. 
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 In the cell viability assay, all the active compounds contain an octylglucoside 
moiety, which suggest that the pharmacophore for the antiproliferative activities of this 
family of compounds is octylglucoside itself (Table 2-2). The IC50 of all the active 
compounds fall within the same range. However, the toxicity and the therapeutic index 
considerably vary with the identity of the fused cyclic molecule with compound 2-1 (with 
a fused [13]-macrodilactone and with a benzyl protection at C2, C3 hydroxyl of the sugar 
moiety) having at most 10-fold higher therapeutic index. In chapter one, we observed that 
the [13]-macrodilactone adopts different shapes depending on the configuration of the 
stereogenic plane and the stereogenic centers on the ring. It is possible that the 
improvement in therapeutic profile of 2-1 resulted from an optimized ring scaffold that 
allowed for better orientation of the pharmacophoric unit – the octyl glucoside – around 
the binding site of its target biomolecule. This suggests that varying or fine-tuning the 
macrocycle attached or fused to a pharmacophore of bioactive small molecules can 
potentially optimize the biological properties of these molecules. 
 
2.4.2 Results and discussion for screening of Chembridge synthetic compound library 
 From the 12, 720 Chembridge synthetic small molecule library, only 1,232 were 
active at 50µM, which is 10% of the total number of molecules screened (Table 2-1). The 
hit rate at lower concentrations is 0.4%, 0.2%, 0.1% at 10µM, 2µM and 400nM 
respectively with no compounds active at concentrations lower than 400nM. This hit rate 
is lower than the hit rate for the natural product compound library, which is expected for 
synthetic compound libraries. However, the structures of the molecule hits from synthetic 
compound library are significantly less complicated than the natural product and thus 
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would be more amenable for SAR studies. Moreover, the synthetic molecule hits are 
more likely to be novel structures (less explored than natural product molecules) with 
potentially novel target and mechanisms of action and thus have huge potential as small 
molecule probes. The most promising hits, among the 19 synthetic small molecules active 
at 400nM, are shown in Fig. 2-5. These six molecules are not toxic at this concentration 
and the wound-area of MDA-MB-231 monolayer treated with these compounds is still 
widely open after 24 hours compared to the DMSO-treated cells. These molecules can be 
good lead compounds for SAR, target ID and mechanisms of action studies.   
 
 
 
 
 
 
 
 
     
 
 
 
 
Figure 2-5. Most promising hits from screening of Chembridge synthetic compound 
library for MDA-MB-231 breast cancer cell migration inhibitors.  
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2.4.3 Results and discussion for screening of Analyticon natural product compound 
library 
 The hit rate for natural product library screening is higher (6%, 1.4%, 1.0%, 0.7%, 
0.7% at 50µM, 10µM, 2µM, 400nM, 80nM respectively) than the hit rate for synthetic 
small molecule screening (Table 2-1). This is to be expected since the natural product is 
most likely to be biologically active. The structures of the natural product hits at 50 µM 
are shown in Appendix with the corresponding toxicity profiles as assessed using a 
qualitative trypan blue assay22. Some of the natural product families found were: 
cinchona alkaloids (5 compounds) – antimalarial; tricothecenes (5) – protein synthesis 
inhibitors; thapsigargins (4) – Sarco/Endoplasmic Reticulum Ca2+ ATPase (SERCA) 
inhibitors; Sesquiterpenes (5); Indoloquinolizidines (4); Cardiac glycosides (9); 
colchicine (1) – microtubule polymerization inhibitor; curvularin (1) and other alkaloids. 
The most promising compounds were further characterized using the quantitative scratch-
wound assay. The antimigartory activity profile of some of these compounds is 
summarized in Table 2-4 and the full data for all the compounds characterized can be 
found in Appendix.  Among these natural product hits, ouabain was chosen as a lead 
compound for further characterization. 
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Table 2-3. Antimigratory profiles of the most promising hits from the analyticon natural 
product compound screening. 
 
Compound MIC (µM) 
IC50 
(µM) 
MLC 
(µM) 
TI 
(µM) 
 
6.25  NA 12.5  2 
 
6.25  5.8  25  4 
curvularin 
3.125  36  > 50  > 16 
cardiac glycoside (ouabain) 
0.061 0.173 >100 >1600 
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2.5 Cardiac glycosides as potent and selective inhibitor of Na+/K+ ATPase 
 
 
 In the course of screening libraries of small molecule and natural product 
compounds for cell migration inhibitors using our scratch-wound assay, cardiac 
glycosides were found to inhibit the migration of the human triple-negative breast cancer 
cell line MDA-MB-231 at submicromolar concentrations. The MDA-MB-231 line is a 
cellular model for triple-negative breast cancer, which is refractory to current 
chemotherapeutic options23. This chapter investigates how cardiac glycoside inhibited the 
migration of MDA-MB-231 breast cancer cells. 
 
2.5.1 Cardiac glycosides – structural features and biological activities  
Cardiac glycosides also referred to as cardiotonic steroids, are a group of natural 
products that share a common ‘unique’ steroidal core that is doubly substituted with a 
sugar at position 3 and an unsaturated lactone ring at position 17 (Fig. 2-6).  
Classification of cardiac glycosides depends on the type of lactone ring attached to the 
steroidal core where those with the lactone 2-furanone are called cardenolides (e.g., 
ouabain – the most highly studied cardiac glycoside, digitoxin and UNBS1450) and those 
with lactone 2-pyrone are called bufadienolides (e.g., bufalin and marinobufagenin). The 
C3 position can be ornate with different types and numbers of sugars such as glucose, 
rhamnose etc. The steroidal core is also ornate with various substituents at different 
positions but the unique cic/cis configuration at the A/B and C/D ring junctions is 
preserved through out the entire cardiac glycoside family. This unique configuration at 
the two ring junctions resulted to a cup-shaped structure - with two distinct α and β 
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surfaces (Fig. 2-6 – top right structure) - rather than the flat planar structure inherent to 
common steroids with trans configurations.  
 
 
Fig. 2-6. Structural properties of cardiac glycosides and representative members of 
cardiac glycoside family. 
 
A number of cardiac glycosides such as digitoxin have long been used as positive 
inotropic drugs for treatment of congestive heart failure by inhibiting the Na+ and K+ 
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antiport activity of Na+/K+ ATPase24. Over the last 20 years, interest in cardiac glycosides 
has grown tremendously due to their promising anti-cancer properties25 . The steroid core 
with distinct cis confiugrations at the A/B and C/D ring junctures is the active 
pharmacophore26 . It is the minimum structure required for Na+ pump inhibition through 
induction of protein conformational change at the receptor level. The lactone ring is not 
rigorously part of the pharmacophore but it amplifies the affinity of the steroid core with 
the protein. The sugar moiety affects the potency as well as the pharmacokinetic and 
pharmacodynamic properties of the cardiac glycosides27. This SAR information is only a 
fraction of the numerous studies on the SAR of various cardiac glycosides with respect to 
inhibition of Na+/K+ ATPase and its anti-cancer activities. However, no SAR study that is 
focused on the antimigratory activity of cardiac glycosides in breast cancer cells has been 
reported. 
 
2.5.2 Na+/K+ ATPase – a multifunctional protein 
 Na+/K+ ATPase, the largest member of P-type cation pumps, is responsible for the 
transport of three Na+ ions out of and two K+ ions into the cell against their physiological 
concentration gradient28. This transport is powered by ATP hydrolysis and is estimated to 
account for 30% of all cell’s energy consumption at rest29. Active transport of Na+ and K+ 
ions in and out of the cell generates an electric potential gradient across the plasma 
membrane and maintains the resting potential of cells and thus the activity of this pump is 
critical for regulation of cell volume, contraction of heart muscle cells and mobilization 
of ions such as calcium and other molecules in and out of the cell28.  
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Fig. 2-7. Cartoon representation of X-ray cystal structure of the high-affinity Na+/K+ 
ATPase E2P–ouabain complex (3.4 A resolution)30. The E2P–ouabain complex is 
depicted using the following color codes: red [nucleotide binding (N) domain], blue 
[phosphorylation (P) domain], light yellow [actuator (A) domain], orange (αM1–2), teal 
(αM3–4), purple (αM5–6), brown (αM7–10), green (β-subunit), and deep pink (γ-
subunit). The CTS binding site is marked CTS. Ouabain is represented by yellow sticks, 
Mg2+ and the three water molecules by light green and red spheres, respectively. The 
figure was reused from reference 30. 
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 In general the Na+/K+ ATPase consists of three subunits (Fig. 2-7)30. The larger α 
subunit is the catalytic site. It contains the nucleotide binding (N), phosphorylation (P), 
and actuator (A) domains, and the biniding sites for Na+, K+, Mg2+ as well as the highly 
conserved cardiac glycoside binding site in a vestibule formed by the αM1-M6 helices. It 
also contains the controversial phosphorylation sites proposed to be involved in the 
signaling function of the Na+/K+ pump31. The β subunit is the extracellular glycoprotein 
(green) mainly important for the recruitment of the α subunit to the plasma membrane. 
The γ (FXYD) subunit regulates the kinetic properties of the pump as well as its tissue 
specificity. To add to the complexity of this pump, the α and β subunits exists in different 
isoforms depending on the cell type: the α subunit exists in four isoforms (α1-4) while the 
β in three (β1-3)28. 
 Besides the ion-transport function, the Na+/K+ ATPase also probably has a 
signaling function. One theory is that a population of non-pumping Na+/K+ ATPase exist 
in a caveolae and forms a multi-protein signaling complex comprised of Src kinase, 
epidermal growth-factor receptor (EGFR), inositol 1,4,5 – triphosphate (IP3) receptor, 
and caveolins31. This signaling complex was proposed to activate two downstream 
signaling pathways. The first one is through the IP3 receptor-mediated calcium release 
that affects intracellular calcium oscillation31c. The second one is a protein-kinase 
cascade initiated by Src31a, 31b. These signaling cascades affect various cellular processes 
such as cell growth, motility, gene expression and some metabolic pathways. 
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2.5.3 Context-dependent dual mechanisms of actions of cardiac glycosides 
  Upon binding of cardiac glycosides to the α subunit of Na+/K+ ATPase, various 
biological and physiological effects were observed depending on the concentration of 
cardiac glycosides and the cell type used. Two mechanisms explain the sometimes, 
opposing cellular and physiological effect of cardiac glycoside32.  
 
2.5.3.1 The classical “Na+ lag” model 
 The Na+ lag model explains the positive inotropic effect of cardiac glycoside and 
its use as drugs for treatment of cardiac arrhythmia33. At concentrations >100 nM, cardiac 
glycosides cause the classical inhibition of ion transport function of the Na
+
/K
+
 ATPase. 
This inhibition leads to an increase in intracellular Na
+
 ion which then activates the 
reverse mode of Na
+
/Ca
2+
 exchanger resulting in an increased intracellular Ca
2+
 
concentration. Increase in intracellular calcium leads to increase in muscle contraction, 
blood pressure and Na+ excretion (Fig. 2-8a). 
 
2.5.3.2 The Na+K+ ATPase signalosome  model 
 The receptor function of Na
+
/K
+
 ATPase is explained by the Na
+
/K
+
 ATPase 
signalosome model31. This model calls for the existence of a population of nonpumping 
Na
+
/K
+
 ATPases that resides in a caveoli and act as a scaffold for the assembly of multi-
protein signaling domain that transmits signals to different intracellular compartments. 
Some members of this complex that has been identified include Src kinase, epidermal 
growth-factor receptor (EGFR), inositol 1,4,5-triphosphate (IP3) receptor and caveolins. 
The model explains that low concentrations of ouabian is not enough for the inhibition of 
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the pumping Na
+
/K
+
 ATPase but is enough to activate the non pumping population and 
trigger a signaling cascade that affects a number of cellular processes such as gene 
expression, proliferation and adhesion.  
 At least two signaling mechanisms were proposed to get activated by binding of 
cardiac glycosides to the Na
+
/K
+
 ATPase signalosome. The first is the signaling through 
alterations in intracellular calcium oscillations31c. Although not yet fully defined, it was 
proposed that phospholipase C (PLC) and IP3 are recruited in the Na
+
/K
+
 ATPase 
signalosome and forms a functional microdomain. This brings the cytosolic part of the 
sodium pump in direct contact with IP3 receptor of the endoplasmic reticulum, which 
results to repeated transient oscillation of calcium ions. The other signaling proposed is 
through Ras activation31a, 31b (Fig. 2-8b). Binding of low concentrations of cardiac 
glycoside to the Na
+
/K
+
 ATPase signalosome releases Src, which transactivates the 
EGFR that eventually lead to activation of mitogen-activated protein (MAP) kinase 
cascade that affects various cellular processes under the control of MAP kinase such as 
gene expression, proliferation and some metabolic processes. 
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2.6 Investigation of the antimigratory mechanism of action of cardiac glycosides in 
MDA-MB-231 breast cancer cell migration 
 
2.6.1 Motivation and research question 
 The dual function of the Na+/K+ ATPase result in dual mechanisms of actions 
attributed to cardiac glycoside’s biological activities. The specific operative mechanism 
of action of cardiac glycosides is highly dependent on the concentration of cardiac 
glycoside and the cell type used.  Some examples of the context-dependent mechanism of 
action of cardiac glycoside are discussed below. 
 Some cardiac glycosides inhibit the migration and proliferation of various cell 
types without affecting the ion-transport function of the Na
+
/K
+
 ATPase, thus supporting 
the nonclassical Na
+
/K
+
 ATPase signalosome model for mode of action of cardiac 
glycosides. Marinobufagenin, an endogenous mammalian cardiotonic steroid inhibits 
proliferation and growth factor induced migration and invasion of cytotrophoblast and 
Chinese hamster ovarian cells in vitro at low nanomolar concentration34 . The mechanism 
involved a decrease in ERK1/2 activity and activation of p38 and Jnk pathways. Since 
ouabain showed similar activities in both cell lines, they speculated that Na+/K+ ATPase 
might be involved; however, no direct correlation was made between inhibition of cell 
migration and inhibition of Na+/K+ ATPase35. UNBS-1450 is another novel cardenolide 
that inhibited the proliferation and migration of non-small cell lung cancer cells, glioma 
cells, prostate cancer cells and metastatic melanoma cells at concentrations that does not 
affect the ion transport activity of the pump36. Inhibition of the α sub-unit of Na+/K+ 
ATPase by UNBS-1450 led to a sharp decrease in intracellular ATP concentration 
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causing disorganization of actin cytoskeleton and induction of proautophagic cytotoxic 
effects37.  
 After discovering that cardiac glycosides inhibit the migration of MDA-MB-231 
cells, we endeavored to define the specific role of Na+/K+ ATPase (classical versus 
nonclassical) in migration of MDA-MB-231 breast cancer cells. Understanding which of 
the two functions of Na+/K+ ATPase is operative in the observed antimigratory activities 
of cardiac glycoside in MDA-MB-231 breast cancer cell migration can contribute to a 
fundamental understanding of triple negative breast cancer migration and can potentially 
open up new avenues for therapeutic interventions. 
 
2.6.2 Research design and strategy 
 To investigate which function of the Na
+
/K
+
 ATPase is operative in the 
antimigratory activity of cardiac glycosides (CGs); we developed a strategy called 
correlative SAR. Traditional SAR studies guide improvements of small molecule potency 
and selectivity for a given target. On the other hand, we define correlative SAR as a 
strategy to expand the use of existing biologically active compounds to address some of 
the major challenges in the postgenomic era: annotating protein functions and linking 
those functions to an observed phenotype. In contrast to traditional SAR, correaltive SAR 
takes advantage of a distinct pattern of structural requirements for activity by a group of 
related molecules (SAR profile) across a series of assays. The SAR profiles are then used 
to establish relationships between a protein or cellular system and bona fide biological 
processes, that is, linking specific protein function to a cellular phenotype (Fig. 2-9). 
Direct correlation of SAR profiles for protein function and a cellular phenotype then 
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implicates a role for the protein in the phenotype. The correlative SAR strategy is 
especially useful for multifunctional proteins and moonlighting proteins38. Correlative 
SAR employs small molecule probes and thus shares the complementarity and 
advantages of small molecules over genetics and RNA interference techniques for 
annotating protein functions.  
 In this study, we use correlative SAR to determine what role the Na+/K+ ATPase 
plays (classical versus non-classical) in migration of MDA-MB-231 breast cancer cells 
(Fig. 2-9). Our strategy first involved synthesis of analogs containing modifications on 
key parts of ouabain and digitoxin – two widely studied cardiac glycosides. The analogs 
contain a modification on the sugar, steroid core or lactone ring of each CG. Next, SAR 
was established at different levels of resolution with respect to inhibition of cell 
migration (cellular), inhibition of the Na
+
/K
+
 ATPase activity in vitro (molecular), and 
orientation in the cardiac glycoside binding site of Na
+
/K
+
 ATPase (atomic). We 
evaluated whether inhibition of cell migration was separable from inhibition of the 
Na
+
/K
+
 antiport pump by correlating the SAR profiles of ouabain in each of these assays. 
In addition, to determine whether the inhibition of cell migration resulted from general 
inhibition of the Na
+
/K
+
 ATPase or if it is confined to an effect of CGs, other structurally 
unique Na
+
/K
+
 ATPase inhibitors were tested for their antimigratory activity. A small 
molecule inhibitor that does not activate the Src signaling pathway but inhibits the ion 
pump was also tested in the cell migration assay. To our knowledge, no SAR study on the 
antimigratory activity of cardiac glycosides in MDA-MB-231 breast cancer cells has 
been reported prior to this work. Furthermore, the current study shows the utility of 
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correlative SAR to establish links between specific protein functions and cellular 
phenotypes. 
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2.7 Correlative SAR of ouabain and analogs in cellular and molecular level 
2.7.1 Semi-synthesis of ouabain analogs 
 Three analogs of ouabain 2-8 were synthesized (2-9 – 2-11, Scheme 1) by 
methods that had been reported previously in the literature39. The derivatives were 
prepared, starting from ouabain itself, by removal of the sugar moiety (2-9), reduction of 
the lactone ring (2-10) and modification of the steroid core (2-11). Hydrolysis of the 
glycosidic linkage between the L-rhamnose and steroid core provided ouabagenin 2-9. 
Reduction of the butenolide olefin by hydrogenation provided analog 2-10. Compound 2-
11 contains an acetonide group that links the C1 and C19 hydroxyl groups. The analogs 
were chosen because they were synthetically accessible and because they consisted of 
variations of the key structural segments of the parent compound in a way that would 
allow for a reasonably comprehensive SAR profile. 
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Scheme 2-1. Semi-synthesis of ouabain analogs.  
 
2.7.2 SAR profile of ouabain and analogs in MDA-MB-231 breast cancer cell 
migration assay 
 The MDA-MB-231 breast cancer cell line was chosen for the scratch-wound cell 
migration assay. MDA-MB-231, a cellular model for triple negative breast cancer has an 
invasive phenotype and is metastatic in animal models. The assay involved mechanical 
wounding of a confluent monolayer of cells with a pipet tip after treatment with different 
concentrations of compounds or DMSO (vehicle) alone. The progress of wound closure 
was monitored by analysis of digital microscope images of the wounds at different times 
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postwounding. The area of the wound at each time point was calculated with the public-
domain ImageJ program, and statistical significance was tested with a two-tailed 
Student’s t-test. Three independent experiments were done with triplicates for each 
concentration of each compound. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2-10. IC
50
 curves for cell migration inhibition by ouabain 2-8 and analogs 2-9 to 2-
11. 
  
 Based on the IC
50
 values for inhibition of wound closure (Fig. 2-10 and Table 2-
4), none of the synthesized analogs was more potent than the parent compound, ouabain 
2-8 with an IC
50
 of 173 nM. However, the potency of the analogs varied with respect to 
the type of modification made to the structure of 2-8. Ouabagenin 2-9, which lacks the 
sugar moiety, had an IC
50
 value of 790 nM. The olefin of the butenolide was reduced to 
prepare compound 2-10; its IC
50
 of 4.3 µM demonstrates that a simple modification to the 
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lactone segment results in a drop in potency by a factor of 25. It further suggests that the 
olefin is relatively important to the ability of cardiac glycosides to inhibit cell migration. 
A major decrease in potency (178-fold) was observed for ouabain analog 2-11, which 
contains a C1, C19 acetonide group. Modification to the steroid core and specifically the 
introduction of a bulky group on the concave face of the cup-shaped steroid greatly 
reduced the antimigratory activity of ouabain. The SAR profile (pattern of structural 
requirement for activity modulation) for antimigratory activity is: modification on steroid 
core > modification on lactone ring > modification on sugar in decreasing impact on 
potency (Fig. 2-11a). 
 
2.7.3 Correlative SAR of ouabain and analogs in MDA-MB-231 breast cancer cell 
migration assay (cellular level) and Na/K ATPase assay (molecular level) 
 Ouabain is a potent and specific inhibitor of the Na+/K+ ATPase. The Na+/K+ 
ATPase is a transmembrane antiport ion transporter that pumps three Na
+
 ions out of the 
cell for every two K
+
 ions pumped into the cell against their concentration gradients for 
each molecule of ATP hydrolyzed. Besides its ion-transport function, this protein 
complex also functions as a receptor for ouabain and has been implicated in processes 
and key cellular elements that affect cell motility such as cell tight junctions40 cell 
contacts41 and actin dynamics42. We investigated whether the antimigratory effect of 
ouabain was linked to the classical inhibition of Na
+
/K
+
 ATPase or stimulation of its 
receptor function31 using correlative SAR. Specifically, we looked at the SAR profile of 
ouabain in a Na
+
/K
+
 ATPase activity assay and correlated it to the SAR profile for 
antimigratory activity. 
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Table 2-4. IC50 values (µM) for the inhibitory activity of ouabain and analogs in the 
Na+/K+ ATPase assay and cell migration assay 
 
Ouabain and 
analogs 
Na+/K+ ATPase Cell migration 
IC50 (µM) 95% CI IC50 95% CI 
2-8 (ouabain) 0.105 0.031 - 0.352 0.173 0.100-0.300 
2-9 0.669 0.526 – 0.850 0.790 0.637 – 0.979 
2-10 2.6 0.823 – 8.46 4.3 3.02 – 6.21 
2-11 12.4 8.98 – 17.2 30.9 25.2 – 38.0 
 
 
 The SAR profile in Na
+
/K
+
 ATPase inhibition is similar to inhibition of cell 
migration (Table 2-4 and Fig. 2-11a). Compound 2-9, with the cleaved sugar moiety, had 
a potency that is relatively similar to the parent compound ouabain 2-8. This implies that 
for inhibition of Na
+
/K
+
 ATPase activity, as for inhibition of cell migration, the sugar 
moiety is less important than other parts of the molecule. Compound 2-10, with the 
saturated lactone ring, displays the next lowest decrease in potency, while 2-11, with the 
bulky acetonide group on the steroid core, shows the greatest decrease in potency. The 
IC
50
 values of ouabain and its analogs for inhibition of Na
+
/K
+
 ATPase activity and the 
values for inhibition of cell migration fall within the same range. The distinct pattern of 
modulation in Na
+
/K
+
 ATPase activity by ouabain and the analogs, as measured by both 
IC
50
 (Figs. 2-11a,b) and dose–response for ouabain alone (Fig. 2-11c) and for combined 
ouabain and analogs (Fig. 2-11d) correlates well with the pattern observed for their effect 
on cell migration. The correlation suggests that the inhibition of cell migration is directly 
related to the inhibition of Na
+
/K
+
 ATPase activity.  
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2.8 Correlative SAR of digitoxin and analogs in cellular and molecular levels 
 We were curious to see if the SAR results for ouabain apply to other members of 
cardiac glycoside family of natural products. Evidence showed that ouabain and digitalis 
cardiac glycosides develop their effect in different cellular spaces and thus have different 
therapeutic profiles43. Ouabain’s mode of action starts by binding to the α subunit of the 
Na+/K+ pump from the extracellular side.  This binding affects cellular functions either 
through activation of different signal transduction pathways (Src and IP3) or through 
perturbation of intracellular Na+, K+ and Ca+ ion concentrations. Digitalis cardiac 
glycosides such as digitoxin on the other hand penetrates the cell’s interior and interacts 
with intracellular ryanodine receptors leading to the release of Ca2+ from the 
sarcoplasmic reticulum43. To explore if the SAR-correlation results for ouabain applies to 
other cardiac glycosides, analogs of digitoxin were synthesized employing the same 
transformation as that used for ouabain 2-8 followed by correlative SAR. It would be 
interesting to know if the correlative SAR for digitoxin would be similar to ouabain 
despite having different modes of action.  
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2.8.1 Semisynthesis of digitoxin and analogs 
 
 
 
 
 
 
 
 
 
 
  
 
Scheme 2-2. Semi-synthesis of digitoxin analogs 2-13 to 2-15.  
  
 Scheme 2 shows the reactions for the partial synthesis of digitoxin analogs 2-13 to 
2-15. An additional product from the deglycosylation of digitoxin, a side product (2-15a, 
2-15b), was obtained which was found to be a mixture of alkene isomers produced from 
dehydration across the hydroxyl-containing carbon of rings C and D and the carbon 
directly adjacent to it which is at the junction of rings B and C. Similar to ouabain 
analogs, the synthesized digitoxin analogs each contains modification on either the sugar, 
lactone or steroid core. Compound 2-13 contains modification on sugar, compound 2-14 
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on lactone ring while compounds 2-15a and 2-15b contain modification on the cup 
shaped steroidal core. 
  
2.8.2 Correlative SAR of digitoxin and analogs in MDA-MB-231 breast cancer cell 
migration assay (cellular level) and Na+/K+ ATPase assay (molecular level) 
 The same experimental approach (correlative SAR) done on oubain and analogs 
(2-8 to 2-11) was performed on digitoxin and analogs  (2-12 to 2-15). The results (Table 
2-5 and Fig. 2-12) were similar to that of the ouabain series. A SAR trend in cell 
migration inhibition assay was observed in Na+/K+ ATPase assay (Fig. 2-12a). The 
analog in which sugar is cleaved is the most potent (compound 2-13) followed by 
compound 2-14 with modification on the lactone ring and the least potent ones are 
compounds 2-15a and 2-15b with modification on the steroid core. Similar to addition of 
a bulky acetonide group that links the C1 and C19 hydroxyl groups of oubain’s steroidal 
core, introduction of unsaturation to either ring B or C of digitoxin through the 
dehydration of the C-14 hydroxyl greatly reduced the potency of digitoxin. These results 
imply that, similar to oubain, the sugar is not that important while the structure of the 
steroid core is highly necessary for the inhibition of both cell migration and Na+/K+ 
ATPase. However, it seemed like modifying the structure of digitoxin has more 
pronounced effect in its ability to inhibit Na+/K+ ATPase than in its ability to inhibit cell 
migration as shown by the decrease in potency of digitoxin analogs for the two assays 
(Fig. 2-12a). Again, similar to the correlation of oubain SAR, the IC50s of digitoxin for 
both antimigratory and Na+/K+ ATPase assays correlate very well (Fig. 2-12b). This 
result corroborates the initial conclusion that the observed antimigratory effect of cardiac 
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ATPase’s ion-transport function. The direct relationship between inhibition of Na
+
/K
+
 
ATPase ion transport function and inhibition of cell migration seemed to be applicable to 
other members of the cardiac glycoside family of natural products.  
 
Table 2-5. IC50 values (µM) for the inhibitory activity of digitoxin and analogs in Na+/K+ 
ATPase assay and cell migration assay. 
 
Digitoxin and analogs IC50 (µM) Na+/K+ ATPase inhibition 
IC50 (µM) 
cell migration inhibition 
2-12 (digitoxin) 0.005 0.046 
2-13 0.097 0.260 
2-14 0.691 2.15 
2-15a and 2-15b 3.2 10.8 
 
 
 
  
 
 
 
 
 
 
Fig. 2-12.  (a) Decrease in potency of digitoxin analogs in antimigratory assay and 
Na+/K+ ATPase assays. (b) Pearson correlation plot for IC50 values of digitoxin and 
analogs in antimigratory assay and  Na+/K+ ATPase assays. 
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2.9 Correlative SAR of ouabain and analogs at cellular, molecular and atomic level 
 One of the advantages of correlative SAR is its applicability in looking at small 
molecule effects in various level of resolution (cellular, molecular and atomic). 
Depending on the assay used, which probes for specific biological activities (biochemical 
or cellular; in vitro or in cellulo) or specific small molecule-protein interactions (using 
either actual small molecule-protein complex crystal structure or molecular docking 
experiments), the same set of structurally similar molecules can be used to link specific 
biochemical or cellular activities to protein-small molecule interactions at atomic level. 
We used molecular docking experiments to probe for SAR of ouabain and its analogs to 
its binding site on the Na+/K+ ATPase and use correlative SAR to link it to the SAR 
profile in cellular and molecular level discussed previously.  
 
2.9.1 Molecular docking of ouabain and analogs in the α subunit of Na+/K+ ATPase 
 The ouabain binding site on the extracellular side of the α-subunit of the Na
+
/K
+
 
ATPase is located in a cleft between the transmembrane segments αM1 and αM630, 44 
(Fig. 2-13). Two orientations of ouabain to this site were originally proposed, one with 
the lactone ring facing toward the cytoplasmic side, as revealed by X-ray crystal structure 
studies30, 44a, 44b (Figs. 2-13, 2-14) and the other one with the lactone ring facing toward 
the extracellular side, as suggested by a lanthanide-based resonance energy transfer 
(LRET) experiment44c. Regardless of the two orientations of ouabain, all structural and 
functional studies agreed that the location of the cardiotonic steroid binding site is in the 
deep vestibule formed by the tansmembrane helices αM1–M6 (Figs. 2-13, 2-14). Most of 
these transmembrane helices constitute the cation permeation path (mapped in Fig. 2-13 
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and 2-14 as residues in cyan) that traverses the Na
+
/K
+
 pump from one side of the 
membrane to the other and passes through the ion-binding site II45 (Figs. 2-13, 2-14, red 
circle), suggesting that ouabain acts by directly blocking the path of ions to prevent them 
from accessing their binding sites (Figs. 2-13, 2-14). Another possibility is that ouabain 
binding may lock the cation transport region into a configuration that prevents the pump 
from undergoing the conformational change required for ion transport46. Prior to this 
work, no experimental evidence linking ouabain’s orientation to the cation permeation 
path and inhibition of Na
+
/K
+
 ATPase was available.  
 We investigated the interactions of ouabain and its analogs to Na
+
/K
+
 ATPase at 
the atomic level (Figs. 2-15, 2-16) by molecular docking experiments in an effort to 
rationalize the SAR results with respect to inhibition of Na
+
/K
+
 ATPase ion-transport 
function and cell migration. Fig. 2-16 shows the overlay between the docked ouabain and 
analogs and the actual ouabain-Na+/K+ ATPase crystal structure30. We explored how each 
modification on the ouabain structure affects binding energy (evaluated in the form of a 
docking score) and orientation relative to ouabain’s structure in the cocrystal (evaluated 
in terms of a root-mean-square-deviation, RMSD) (Table 2-6). We then correlated the 
SAR profile for calculated RMSD (Fig. 2-17) and binding energy (Fig. 2-18) to the SAR 
profile for inhibition of Na
+
/K
+
 ATPase activity and inhibition of cell migration. 
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 The observations of the structural interactions of ouabain and its analogs with the 
Na
+
/K
+
 ATPase are consistent with the observed experimental SAR profile for their 
inhibition of Na
+
/K
+
 ATPase ion-transport function and breast cancer cell migration. The 
docked analogs 2-9 and 2-10 (Figs. 2-15b,c), which are the two most potent analogs (5× 
and 25× less potent than ouabain, respectively) adapted a similar orientation to the crystal 
structure of ouabain bound to Na
+
/K
+
 ATPase (Fig. 2-15a). The concave nonpolar α-
surface of ouabain 2-8 (Fig. 2-13 - chemdraw) and analogs 2-9 and 2-10 are stabilized by 
hydrophobic residues such as I315, F316, F783, and F786 (Fig. 2-15a-c). The hydroxyl 
groups of the polar β-surface, on the other hand, are stabilized by H-bonding interactions 
(between C19-OH and the highly conserved C14-OH of cardiac glycosides and N111 and 
T797 of αM1 and αM6, respectively). The C14-hydroxyl–T797 interaction for analog 2-
10, however, was slightly shifted, and thus the H-bonding angle was less than ideal (Fig. 
2-17), possibly due to reduction of lactone ring olefin. This could explain the 25× 
decrease in potency observed for both the pump and cell migration inhibition. On the 
other hand, the least potent analog 2-11 (Fig. 2-15d) adapted a different pose in the ion 
permeation path altogether (Figs. 2-15d and 2-18). Analog 2-11 took up a shallow 
position and was oriented in the opposite direction with its polar β-surface facing the 
helices M4 and M5, while the apolar α-surface faced the helices M1, M2, and M6. This 
orientation does not allow for H-bonding interactions with Q111 and T797 (Figs. 2-15d 
and 2-18), residues identified by mutagenesis studies47 to be critical for ouabain’s 
inhibition of Na
+
/K
+
 ATPase. However, the orientation of the docked analog 2-11 is 
possibly stabilized by hydrophobic interactions of I315, F316, and F783 with the steroid 
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rings C and D, and H-bonding interaction of C19-hydroxyl with E117 instead of Q111 
(Figs. 2-15d and 2-18). 
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2.9.2 Correlative SAR of ouabain and analogs in MDA-MB-231 breast cancer cell 
migration assay, Na+/K+ ATPase assay, binding energy and orientation in Na+/K+ 
ATPase binding site 
 The binding energy and RMSD were calculated for the docked compounds to 
quantify the effect of each structural modification on the ouabain-Na
+
/K
+
 ATPase 
interaction. These parameters were then correlated to the experimental results from in 
vitro Na
+
/K
+
 ATPase inhibition and breast cancer cell migration assays (Table 2-6). 
Considering that the docking score is only an approximate measure of true free energies 
of binding, both the IC
50
 values for inhibition of Na
+
/K
+
 ATPase and inhibition of cell 
migration by ouabain and analogs correlate reasonably well with the calculated binding 
energy (Fig. 2-20) for analogs 2-9 and 2-10. That is, analogs 2-9 and 2-10 have less 
negative energy of binding compared with 2-8, although with similar orders of magnitude, 
which is consistent with lower potency. A proper orientation relative to the cardiac 
glycoside binding site seemed to be highly critical to Na
+
-pump inhibition (Fig. 2-19). 
The more negative binding energy calculated for the least potent analog 2-11 probably 
results from a stable analog 2-11–Na
+
/K
+
 ATPase complex (possibly resulting from some 
hydrophobic and H-bonding interactions discussed earlier) (Fig. 2-18), but the orientation 
of analog 2-11 to the ion permeation path might not be as effective in blocking ion 
permeation as that of ouabain. In other words, despite analog 2-11 being more tightly 
bound, it is noticeably positioned in a region of the binding site much closer to the 
surface, and therefore less able to stop the permeation of ions deep inside the pocket (Figs. 
2-16d and 2-17d). On the other hand, both the IC
50
 values for inhibition of Na
+
/K
+
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ATPase and inhibition of cell migration by ouabain analogs correlate very well with the 
RMSD (Fig. 2-19), implying that deviation from ouabain’s orientation in the cation 
permeation of Na
+
/K
+
 ATPase is directly proportional to the decrease in its inhibitory 
activity. 
 
Table 2-6. Calculated binding energies and RMSD of ouabain and analogs from 
molecular docking experiments and the IC50 values for cell migration and Na+/K+ 
ATPase assays 
 
Docked 
ouabain and 
analogs 
Binding 
energy (amber 
score) kcal/mol 
RMSD (non-
hydrogen 
atoms) 
Na+/K+ 
ATPase IC50 
(µM) 
Cell migration 
IC50 (µM) 
2-8 –5420.51 0.0000 0.105 0.173 
2-9 –5399.66 0.5807 0.669 0.790 
2-10 –5412.08 0.9367 2.6 4.3 
2-11 –5584.89 6.5933 12.4 30.9 
 
 
  
Fig. 2-19. (A) Pearson correlation plot for IC
50
 values of ouabain and analogs in the 
Na
+
/K
+
 ATPase assay and the RMSD. (B) Pearson correlation plot for IC
50
 values of 
ouabain and analogs in the cell migration assay and the RMSD. 
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Figure 2-20. (A) Pearson correlation plot for IC
50
 values of ouabain and analogs in the 
Na
+
/K
+
 ATPase assay and the RMSD. (B) Pearson correlation plot for IC
50
 values of 
ouabain and analogs in the cell migration assay and the RMSD. 
 
 
2.10. Antimigratory activities of other Na+/K+ ATPase inhibitors that are not 
structurally related to cardiac glycosides 
 
 To explore whether the inhibition of cell migration results from general inhibition 
of the Na
+
/K
+
 ATPase or is specific for cardiac glycosides, the antimigratory effect of 
other Na
+
/K
+
 ATPase inhibitors that are structurally distinct from cardiac glycosides was 
determined. All of the non-cardiac-glycoside Na
+
/K
+
 ATPase inhibitors tested also 
inhibited cell migration with varying potencies (Table 2-7). Compound 2-16, a 
nonspecific inhibitor of Na
+
/K
+
 ATPase, is the most potent; however, it was also toxic 
and its IC
50
 is very close to its minimum lethal concentration, which is likely due to its 
effect on other cellular targets. The next most potent is compound 2-18. This Na
+
/K
+
 
ATPase inhibitor is particularly interesting because it was reported that, unlike ouabain, it 
does not activate the Na
+
/K
+
 ATPase/Src complex nor does it stimulate the protein kinase 
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cascades48 . Compound 2-18 is a useful small molecule probe since it can inhibit only one 
function (Na
+
/K
+
 ATPase enzymatic activity) of the pump without activating its receptor 
function. This allows exploration and differentiation of the functional consequences of 
the enzymatic versus receptor function of the Na
+
/K
+
 ATPase. Since 2-18 also inhibits 
cell migration, the antimigratory activity of cardiac glycosides does not primarily entail 
activation of the receptor function of Na
+
/K
+
 ATPase. Furthermore, any of the 
compounds tested that inhibit Na
+
/K
+
 ATPase also inhibit MDA-MB-231 breast cancer 
cell migration. Therefore, the cardiac glycosides do not have a unique antimigratory 
effect among inhibitors of the Na
+
/K
+
 ATPase. 
 
Table 2-7. Inhibitory effect of Na+/K+ ATPase inhibitors that are structurally different 
from cardiac glycoside in the Na+/K+ ATPase assay and the cell migration assay 
 
Compounds 
Literature IC50 for 
inhibition of the 
Na+/K+ ATPase 
IC50 for inhibition 
of cell migration 
Minimum lethal 
concentration 
(2-16)        Na3VO4                                 
40nM49 
 
5.6 µM 
15.6 µM 
(2-17) 
19 µM50 
 
 
 
34.4 µM 
 
 
 
 
>250 µM 
 
(2-18) 
1.5 µM 48 
 
 
 
7.86 µM 
 
 
 
>250 µM 
 
 
 
 
O
O OH
OHOH
HO
. xH2O
O
COO-
Br
O
BrBr
-O
Br
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2.11. Hypothesis on how cardiac glycoside’s inhibition of Na+/K+ ATPase leads to 
inhibition of MDA-MB-231 breast cancer cell migration  
 The increase in [Ca
2+
]
i
, through the activation of the reverse Na
+
/Ca
2+
 exchanger 
resulting from the “classical” inhibition of the ion transport function of the Na
+
/K
+
 
ATPase, might explain the observed inhibitory activity of Na
+
/K
+
 ATPase inhibitors in 
MDA-MB-231 breast cancer cell migration. Ca
2+
 signaling is a crucial coordinator of cell 
migration through various mechanisms. Some of these mechanisms include activation of 
myosin light chain kinase (MLCK), modulation of nascent focal adhesions, and 
retraction–adhesion of lamellipodia through local calcium pulses near the leading edge of 
migrating cells51. Consequently, inhibition of key regulators of calcium homeostasis 
affects cell migration. In the wound-closure assay, thapsigargin, a specific and 
irreversible inhibitor of sarco/endoplasmic reticulum Ca
2+
 ATPase (SERCA), inhibited 
the migration of bovine aortic endothelial cells (BAEC). In this migrating BAEC, 
thapsigargin treatment elicited a rapid increase in [Ca
2+
]
i
 due to depletion of Ca
2+
 store 
sites52. Interestingly, through chemical genetic screening using the same wound-closure 
assay, we found that thapsigargin 2-19 and an analog 2-20 inhibited MDA-MB-231 
breast cancer cell migration below their cytotoxic concentration (Fig. 2-21). Besides 
small molecule inhibition, it was reported that siRNA knockdown of SERCA and other 
key Ca
2+
 regulators such as plasma membrane calcium ATPase (PMCA) and components 
of store-operated Ca
2+
 (SOC) influx pathway also altered the basal [Ca
2+
]
i.
 An inverse 
correlation between the effect of small molecule and siRNA knockdown to [Ca
2+
]
i
 and 
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2-19 (tapsigargin) 2-20 (tapsogargin analog)
cell migration was observed, where an increase in [Ca
2+
]
i
 reduced the speed of human 
umbilical vein endothelial cells (HUVECs) and vice versa51b. The aim of the present 
study is to illustrate the utility of correlative SAR as a strategy to link a specific protein 
function of a multifunctional protein to an observed cellular phenotype. Although the 
present study did not explore the effect of Na
+
/K
+
 ATPase inhibitors in Ca
2+
 signaling, 
we showed that the antimigratory effect of Na
+
/K
+
 ATPase inhibitors in MDA-MB-231 
breast cancer cell migration is directly related to inhibition of the ion-transport function 
of the Na
+
 pump. It is established that this classical inhibition of Na
+
/K
+
 ATPase leads to 
an increase in intracellular [Ca
2+
]
I
33 and thus, it is possible that the observed 
antimigratory effect of Na
+
/K
+
 ATPase inhibitors in MDA-MB-231 breast cancer cells 
might be due to the increase in [Ca
2+
]
i
, probably in a similar manner that thapsigargin 
inhibited the migration of this cell line. 
 
 
 
 
 
 
   
Fig. 2-21. Thapsigargin 2-19 and analog 2-20 were found to inhibit the migration of 
MDA-MB-231 breast cancer cell from chemical genetic scre ening. Both 2-19 and 2-20 
were toxic above 10 µM (Maximum Lethal Concentration) in MDA-MD-231 and have 
antimigratory activity above 400 nM (Minimum Inhibitory Concentration). 
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2.12 Conclusion 
 
 In this study, correlative SAR of cardiac glycosides and analogs were used to link 
the ion transport function of Na
+
/K
+
 ATPase to MDA-MB-231 breast cancer cell 
migration. Analogs of representative cardiac glycosides ouabian and digitoxin that 
contain modifications in each part of the tripartite cardiac glycoside were synthesized. 
The effect of each structural modification on cardiac glycosides to their activities in both 
inhibition of Na
+
/K
+
 ATPase (molecular) and cell migration (cellular) provided a distinct 
pattern (SAR profile). Our results showed that modification on steroid core > 
modification on lactone ring > modification on sugar in decreasing impact on potency. 
These SAR profiles correlated in both experimental assays, showing a direct relationship 
between inhibition of MDA-MB-231 breast cancer cell migration and inhibition of 
Na
+
/K
+
 ATPase ion transport function. The interactions of ouabain and analogs to Na
+
/K
+
 
ATPase were also investigated at the atomic level using molecular docking experiments. 
Their activities in both inhibition of Na
+
/K
+
 ATPase and cell migration correlated quite 
well with the degree of similarity in orientation with respect to the known ouabian 
orientation and reasonably well with binding energy calculations, provided that the 
analog completely blocks the permeation path. A cardiac glycoside analog may have a 
higher binding energy to Na
+
/K
+
 ATPase, but if its orientation does not allow for 
effective blocking of the ion permeation path, binding of that analog may not result in 
efficient inhibition. 
 Based on these results, we conclude that it is the ion-transport function of Na
+
/K
+
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ATPase that is involved in MDA-MB-231 breast cancer cell migration and not the 
receptor function. This conclusion is further corroborated by the observed inhibition of 
breast cancer cell migration by other Na
+
/K
+
 ATPase inhibitors that are structurally 
distinct from cardiac glycosides. In particular, a Na
+
/K
+
 ATPase inhibitor that does not 
activate Na
+
/K
+
 ATPase/Src complexes nor the protein kinase cascades still inhibited cell 
migration, implying that the antimigratory effect of Na
+
/K
+
 ATPase inhibitors does not 
involve activation of its receptor function. We speculate that a mechanism in which 
perturbation of intracellular Na
+
 and K
+
 and therefore Ca
+
 ion concentrations leads to 
inhibition of breast cancer cell migration. Further studies on how exactly perturbations of 
ion homeostasis affect the migration of MDA-MB-231 cells could help contribute to 
understanding the overall mechanism of triple negative breast cancer cell migration. This 
report also provides an example of how correlative SAR can help establish new 
relationships between specific biochemical functions and higher-level cellular processes 
by providing a quantitative way to link the effect of small molecules at the cellular, 
molecular, and atomic level. 
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2.13 Experimental 
 
Chemical genetic screening for MDA-MB-231 breast cell migration inhibitors 
 
A previously published high-throughput protocol for screening of inhibitors of epithelial 
cell sheet migration (ref) was adopted for chemical genetic screening (of around 12,000 
natural products and synthetic compounds) of MDA-MB 231 breast cancer cell migration 
inhibitors.  MDA-MB 231 breast cancer cells were plated on 96-well tissue culture plates 
and cultured at 37"°C and 5"% CO2 with Dulbecco's Modified Eagle Medium and 10% 
FBS until confluent. Test compounds from the library (dissolved in DMSO) and DMSO 
alone (as a control) were added with fresh medium to the confluent cell cultures at an 
initial screening concentration of 50 µm (1% v/v DMSO/medium). We found that 1% 
DMSO had no detectable effect on the migration or growth of MDA-MB 231 cells 
compared to medium alone. After 30 min, the cell monolayers were scraped with a 
micropipet tip to produce oval-shaped wounds of 0.5–1.0 mm2 in area. Progress of wound 
closure was followed by observation on an inverted microscope at 12 h and 24 h. At each 
time point, wounds were scored as either closed or opened realative to DMSO control to 
determine possible inhibitory or acceleratory effects of the test compounds on wound 
closure. Compounds that resulted in wounds that were still open after the wounds for the 
control DMSO treatments were closed were considered antimigratory. Compounds that 
were antimigratory at 50 µM were cherry-picked, pooled and screened again at lower 
concentrations (10 µM, 2 µM, 400 nM and down to 16 nM) to gauge the compound’s 
potency.   
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Quantitative cell migration assay 
  
Quantitative wound closure assay was performed on compounds that were active at sub 
micromolar concentrations to evaluate their concentration-response profiles. Similar to 
the primary wound closure assay, confluent monolayers of MDA-MB-231 breast cancer 
cells were wounded 30 min after treatment with different concentrations of these 
compounds or DMSO alone. Instead of a qualitative open or close wound evaluation, the 
progress of the wound closure was followed quantitatively by taking digital images of the 
wounds at 3 h, 6 h, 12 h and 24 h post-wounding. Using the NIH ImageJ software 
( http://rsbweb.nih.gov/ij/), the remaining open area of the wound at each time point was 
calculated by tracing the wound margin in each images. Microsoft Excel and GraphPad 
Prism software were used to tabulate and analyze the corresponding data.  GraphPad 
Prism software was used to determine the IC50 for inhibition of wound closure from dose-
response data and two-tailed Student’s t-test (p > 0.05) was used to statistically determine 
significant differences. Among the antimigratory compound hits from screening of 
MDA-MB 231 breast cancer cell migration inhibitors, cardiac glycosides were chosen for 
further characterization of their mechanism of action in relation to inhibition of MDA-
MB 231 breast cancer cell migration. Analogs of reperesentative cardiac glycosides, 
ouabain and digitoxin were synthesized and analyzed for their effect on MDA-MB 231 
breast cancer cell migration using the same quantitative cell migration assay.   
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Molecular Docking  
 
A model of the complex between oubain bound sodium-potassium transporting ATPase 
was obtained from the available crystallographic data at the RSCB website (4HYT) and 
refined using Chimera GUI. Duplicate chains (C, D, and E) and chain G were deleted, as 
they were not needed in the ligand docking. All residues were protonated based on 
neutral pH after the assignment of bond orders using the Dock prep tool in Chimera. 
Histidine tautomers were determined based on the ability to form Hydrogen bonds with 
the neighboring residues. Ions, solvent molecules, extraneous molecules and substitution 
codes for the side chains were also deleted.  
 
The protein was assigned Amber force field parameters while antechamber was used to 
assign the ligand and non-standard residues’ parameters. The charge set used for the 
ligand was AM1-BCC charges; the structure was then minimized and duplicated – one 
part had the ligand deleted (the receptor) while the other had the protein part deleted (the 
ligand). The ligand was duplicated again one part was modified and minimized, while the 
other served as a control.  
Docking followed the standard docking procedure in the Dock6 manual. Molecular 
surface was constructed using the dms program inbuilt in UCSF’s Chimera using a probe 
radius of 1.4Å. The spheres were then generated using sphgen_cc implemented in Dock6 
suite and the X-ray structure (reference) ligand was used to select the hotspot upto 10Å 
from the position of the heavy atoms of the reference ligand. A site box and the generated 
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spheres were then prepared using the showbox and showsphere modules. The grid box 
enclosing the selected spheres had an extra 5Å added in every dimension. Grids were 
computed using a grid spacing of 0.3A, distance dielectric of 4 with a combination of 
contact and energy scores using the Van der Waals parameters of Amber99 force field. 
 
Docking was performed through grid scoring and automated ligand orientation and 
matching first with a rigid ligand then choosing 10 best poses and redocking while 
keeping the ligand flexible. To account for receptor flexibility an ensemble docking was 
attempted with Amber force field parameters and running a molecular dynamics 
simulation; this instead did not give an improvement in the docking poses but produced 
fluctuations in the structure. The final rescoring was done on the top most poses from the 
grid score, using amber score (binding energy) 
 
 
 
 
 
 
 
 
 
 
 
 166 
In vitro Na+/K+ ATPase assay  
 
The enzymatic activity of Na+/K+ ATPase (purchased from Sigma as lyophilized powder 
from porcine cerebral cortex) was measured by colorimetric quantification of Pi released 
during ATP hydrolysis. A previously published procedure47 was adapted with some 
modifications. The reaction was started by incubating 10µL of Na+/K+ ATPase (600 
units/mL) with 2.5 µL of KCl/NaCl solution (45mM KCl and 2M NaCl) at 37oC for 30 
minutes with either 5 µL DMSO (control) or 5 µL test compounds in 67.5 µL buffer 
(24mM Tris HCl buffer with 0.68 mM Ethylenediaminetetraacetic acid and 6.0 mM 
Magnesium chloride, pH 7.8). 5µL of 80mM ATP was then added and the reaction 
mixture was incubated again at 37oC for 15 minutes. 30 µL of 100% w/v Tricholoroacetic 
acid was then added to the reaction mixture followed by centrifugation for 3 minutes. 
50µL of the supernatant was transferred to a 96-well plate containing 100µL of Taussky-
Shorr reagent. The absorbance at 660nm was read after incubation at room temperature 
for 5 minutes. The concentration of phosphate released in the enzymatic reaction was 
measured from the absorbance at 660nm using a standard curve. The effect of test 
compounds on enzymatic activity (percent inhibition) was calculated by taking the ratio 
of the concentration of liberated phosphate after compound treatment against that of 
DMSO control. Dose-response (using 9 concentrations starting from 1mM to 15 nM) for 
Na+/K+ ATPase inhibition was obtained for each test compounds for 3 trials with 3 
replicates each trial. GraphPad Prism software was used to determine the IC50 for Na+/K+ 
ATPase inhibition from dose-response data and two-tailed Student’s t-test (p > 0.05) was 
used to statistically determine significant differences. GraphPad Prism software was also 
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used to calculate and generate correlation plots for the inhibitory effect of test compounds 
on the Na+/K+ ATPase enzymatic activity and MDA-MB 231 breast cancer cell migration 
using Pearson correlation. 
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Figure A-1. Dose-response curve for ouabain 2-8 effect in MDA-MB-231 wound closure. 
IC50 values were determined by nonlinear regression analysis with GraphPad prism 
software. It was calculated for inhibition of wound closure at 24 h post-wounding with 
normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of wound 
closure at 24 h by ouabain 2-8 is 173 nM.  
 
 
Sigmoidal dose-response (variable 
slope)   
Best-fit values   
Bottom 59.96 
Top 101.5 
LogEC50 -6.762 
HillSlope -0.9504 
EC50 1.732e-007 
Std. Error   
Bottom 0.8770 
Top 3.693 
LogEC50 0.1194 
HillSlope 0.1846 
95% Confidence Intervals   
Bottom 58.21 to 61.71 
Top 94.16 to 108.9 
LogEC50 -7.000 to -6.523 
HillSlope -1.319 to -0.5824 
EC50 1.001e-007 to 2.996e-007 
Goodness of Fit   
Degrees of Freedom 77 
R² 0.8889 
Absolute Sum of Squares 1909 
Sy.x 4.980 
Number of points   
Analyzed 81 
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Figure A-2. Dose-response curve for ouabain 2-8 effect in in vitro Na+/K+ ATPase 
inhibition. IC50 values were determined by nonlinear regression analysis with GraphPad 
prism software. It was calculated with normalization to DMSO control. The calculated 
IC50 value for inhibition of the Na+/K+ ATPase activity by ouabain 2-8 is 105 nM.  
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Figure A-3. Dose-response curve for ouabain 2-9 effect in MDA-MB-231  wound 
closure. IC50 values were determined by nonlinear regression analysis with GraphPad 
prism software. It was calculated for inhibition of wound closure at 24 h post-wounding 
with normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of wound 
closure at 24 h by 2-9 is 790 nM.  
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Figure A-4. Dose-response curve for ouabain 2-9 effect in in vitro Na+/K+ ATPase 
inhibition. IC50 values were determined by nonlinear regression analysis with GraphPad 
prism software. It was calculated with normalization to DMSO control. The calculated 
IC50 value for inhibition of the Na+/K+ ATPase activity by 2-9 is 669 nM.  
 
 
 
Sigmoidal dose-response 
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Best-fit values   
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HillSlope -1.109 
EC50 6.687e-007 
Std. Error   
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95% Confidence Intervals   
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Top 1.067 to 1.152 
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Figure A-5. Dose-response curve for ouabain 2-10 effect in MDA-MB-231  wound 
closure. IC50 values were determined by nonlinear regression analysis with GraphPad 
prism software. It was calculated for inhibition of wound closure at 24 h post-wounding 
with normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of wound 
closure at 24 h by 2-10 is 4.33 µM.  
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Sigmoidal dose-response 
(variable slope)   
Best-fit values   
Bottom 56.73 
Top 100.5 
LogEC50 -5.363 
HillSlope -1.034 
EC50 4.333e-006 
Std. Error   
Bottom 1.513 
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LogEC50 0.07826 
HillSlope 0.1766 
95% Confidence Intervals   
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Top 97.62 to 103.4 
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HillSlope -1.386 to -0.6814 
EC50 3.025e-006 to 6.207e-006 
Goodness of Fit   
Degrees of Freedom 77 
R² 0.9028 
Absolute Sum of Squares 2888 
Sy.x 6.124 
Number of points   
Analyzed 81 
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Sigmoidal dose-response 
(variable slope)   
Best-fit values   
Bottom 0.5248 
Top 0.8781 
LogEC50 -5.579 
HillSlope -0.8981 
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Std. Error   
Bottom 0.03701 
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LogEC50 0.2544 
HillSlope 0.4251 
95% Confidence Intervals   
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Top 0.8219 to 0.9343 
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HillSlope 
-1.743 to -
0.05282 
EC50 
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Goodness of Fit   
Degrees of Freedom 95 
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Number of points   
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Figure A-6. Dose-response curve for ouabain 2-10 effect in in vitro Na+/K+ ATPase 
inhibition. IC50 values were determined by nonlinear regression analysis with GraphPad 
prism software. It was calculated with normalization to DMSO control. The calculated 
IC50 value for inhibition of the Na+/K+ ATPase activity by 2-10 is 2.6 µM.  
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Figure A-7. Dose-response curve for 2-11 effect in MDA-MB-231  wound closure. IC50 
values were determined by nonlinear regression analysis with GraphPad prism software. 
It was calculated for inhibition of wound closure at 24 h post-wounding with 
normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of wound 
closure at 24 h by 2-11 is 30.9 µM.  
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Figure A-8. Dose-response curve for ouabain 2-11 effect in in vitro Na+/K+ ATPase 
inhibition. IC50 values were determined by nonlinear regression analysis with GraphPad 
prism software. It was calculated with normalization to DMSO control. The calculated 
IC50 value for inhibition of the Na+/K+ ATPase activity by 2-11 is 12.4 µM.  
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Absolute Sum of Squares 2.339 
Sy.x 0.1569 
Number of points   
Analyzed 99 
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Figure A-9. Dose-response curve for 2-12 effect in MDA-MB-231  wound closure. IC50 
values were determined by nonlinear regression analysis with GraphPad prism software. 
It was calculated for inhibition of wound closure at 24 h post-wounding with 
normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of wound 
closure at 24 h by 2-12 is 46 nM.  
 
 
Sigmoidal dose-response 
(variable slope)   
Best-fit values   
Bottom 47.24 
Top 105.7 
LogEC50 -7.336 
HillSlope -0.6929 
EC50 4.609e-008 
Std. Error   
Bottom 3.239 
Top 7.263 
LogEC50 0.2251 
HillSlope 0.2258 
95% Confidence Intervals   
Bottom 40.78 to 53.70 
Top 91.21 to 120.2 
LogEC50 -7.785 to -6.887 
HillSlope -1.143 to -0.2426 
EC50 1.639e-008 to 1.296e-007 
Goodness of Fit   
Degrees of Freedom 77 
R² 0.7394 
Absolute Sum of Squares 11959 
Sy.x 12.46 
Number of points   
Analyzed 81 
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Figure A-10. Dose-response curve for digitoxin 2-12 effect in in vitro Na+/K+ ATPase 
inhibition. IC50 values were determined by nonlinear regression analysis with GraphPad 
prism software. It was calculated with normalization to DMSO control. The calculated 
IC50 value for inhibition of the Na+/K+ ATPase activity by 2-12 is 5.13 nM.  
 
 
 
Sigmoidal dose-response 
(variable slope)   
Best-fit values   
Bottom 0.2608 
Top 0.6049 
LogEC50 -7.290 
HillSlope -1.061 
EC50 5.129e-008 
Std. Error   
Bottom 0.01075 
Top 0.01286 
LogEC50 0.09477 
HillSlope 0.2168 
95% Confidence 
Intervals   
Bottom 0.2361 to 0.2856 
Top 0.5752 to 0.6345 
LogEC50 -7.508 to -7.071 
HillSlope -1.560 to -0.5606 
EC50 3.101e-008 to 8.484e-008 
Goodness of Fit   
Degrees of Freedom 8 
R² 0.9863 
Absolute Sum of 
Squares 0.003758 
Sy.x 0.02167 
Number of points   
Analyzed 12 
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Figure A-11. Dose-response curve for 2-13 effect in MDA-MB-231  wound closure. IC50 
values were determined by nonlinear regression analysis with GraphPad prism software. 
It was calculated for inhibition of wound closure at 24 h post-wounding with 
normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of wound 
closure at 24 h by 2-13 is 261 nM.  
 
Sigmoidal dose-response 
(variable slope)   
Best-fit values   
Bottom 64.65 
Top 100.4 
LogEC50 -6.583 
HillSlope -2.298 
EC50 2.614e-007 
Std. Error   
Bottom 1.451 
Top 1.910 
LogEC50 0.06828 
HillSlope 1.250 
95% Confidence Intervals   
Bottom 61.76 to 67.55 
Top 96.58 to 104.2 
LogEC50 -6.719 to -6.446 
HillSlope -4.792 to 0.1947 
EC50 
1.911e-007 to 3.577e-
007 
Goodness of Fit   
Degrees of Freedom 77 
R² 0.7800 
Absolute Sum of Squares 5901 
Sy.x 8.754 
Number of points   
Analyzed 81 
 188 
 
-9.5 -8.5 -7.5 -6.5 -5.5 -4.5 -3.5 -2.5
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
1.2
1.3
Log [digitoxigenin]
%
 in
hi
bi
tio
n 
no
rm
al
iz
ed
 a
ga
in
st
 D
M
SO
 c
on
tro
l
O O
O
OH
H3C
H
OH3C
OH
O
OH
HO
H
H3C
H
CH3
OH
HO
H
O O
digitoxigenin 2-13
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-12. Dose-response curve for digitoxin 2-13 effect in in vitro Na+/K+ ATPase 
inhibition. IC50 values were determined by nonlinear regression analysis with GraphPad 
prism software. It was calculated with normalization to DMSO control. The calculated 
IC50 value for inhibition of the Na+/K+ ATPase activity by 2-13 is 97 nM.  
 
 
Sigmoidal dose-response 
(variable slope)   
Best-fit values   
Bottom 0.1201 
Top 0.9911 
LogEC50 -7.014 
HillSlope -1.031 
EC50 9.692e-008 
Std. Error   
Bottom 0.01594 
Top 0.01240 
LogEC50 0.04118 
HillSlope 0.08961 
95% Confidence 
Intervals   
Bottom 0.08737 to 0.1528 
Top 0.9657 to 1.017 
LogEC50 -7.098 to -6.929 
HillSlope -1.215 to -0.8472 
EC50 
7.978e-008 to 1.177e-
007 
Goodness of Fit   
Degrees of Freedom 27 
R² 0.9906 
Absolute Sum of 
Squares 0.03968 
Sy.x 0.03833 
Number of points   
Analyzed 31 
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Figure A-13. Dose-response curve for 2-14 effect in MDA-MB-231  wound closure. IC50 
values were determined by nonlinear regression analysis with GraphPad prism software. 
It was calculated for inhibition of wound closure at 24 h post-wounding with 
normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of wound 
closure at 24 h by 2-14 is 2.15 µM.  
Sigmoidal dose-response 
(variable slope)   
Best-fit values   
Bottom 63.81 
Top 99.85 
LogEC50 -5.667 
HillSlope -2.442 
EC50 2.154e-006 
Std. Error   
Bottom 1.657 
Top 1.420 
LogEC50 0.08475 
HillSlope 0.6761 
95% Confidence Intervals   
Bottom 60.51 to 67.12 
Top 97.02 to 102.7 
LogEC50 -5.836 to -5.498 
HillSlope -3.791 to -1.094 
EC50 1.460e-006 to 3.179e-006 
Goodness of Fit   
Degrees of Freedom 77 
R² 0.8084 
Absolute Sum of Squares 5368 
Sy.x 8.349 
Number of points   
Analyzed 81 
 190 
 
-9.5 -8.5 -7.5 -6.5 -5.5 -4.5 -3.5 -2.5
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
1.2
1.3
Log [hydrogenated digitoxin]
%
 in
hi
bi
tio
n 
no
rm
al
iz
ed
 a
ga
in
st
 D
M
SO
 c
on
tro
l
O O
O
OH
H3C
H
OH3C
OH
O
OH
HO
H
H3C
H
CH3
OH
HO
H
O O
hydrogenated digitoxin 2-14
 
 
 
 
Figure A-14. Dose-response curve for digitoxin 2-14 effect in in vitro Na+/K+ ATPase 
inhibition. IC50 values were determined by nonlinear regression analysis with GraphPad 
prism software. It was calculated with normalization to DMSO control. The calculated 
IC50 value for inhibition of the Na+/K+ ATPase activity by 2-14 is 691 nM.  
 
 
 
Sigmoidal dose-response 
(variable slope)   
Best-fit values   
Bottom 0.06876 
Top 1.063 
LogEC50 -6.161 
HillSlope -0.8172 
EC50 6.907e-007 
Std. Error   
Bottom 0.04976 
Top 0.03670 
LogEC50 0.1228 
HillSlope 0.1722 
95% Confidence 
Intervals   
Bottom -0.03300 to 0.1705 
Top 0.9877 to 1.138 
LogEC50 -6.412 to -5.910 
HillSlope -1.169 to -0.4650 
EC50 
3.874e-007 to 1.231e-
006 
Goodness of Fit   
Degrees of Freedom 29 
R² 0.9412 
Absolute Sum of Squares 0.3375 
Sy.x 0.1079 
Number of points   
Analyzed 33 
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Figure A-15. Dose-response curve for 2-15a, 2-15b effects in MDA-MB-231  wound 
closure. IC50 values were determined by nonlinear regression analysis with GraphPad 
prism software. It was calculated for inhibition of wound closure at 24 h post-wounding 
with normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of wound 
closure at 24 h by 2-15a, 2-15b is 10.8 µM.  
 
 
Sigmoidal dose-response 
(variable slope)   
Best-fit values   
Bottom 53.76 
Top 99.88 
LogEC50 -4.968 
HillSlope -4.461 
EC50 1.077e-005 
Std. Error   
Bottom 0.8194 
Top 0.4336 
LogEC50 0.01024 
HillSlope 0.4238 
95% Confidence Intervals   
Bottom 52.12 to 55.39 
Top 99.01 to 100.7 
LogEC50 -4.988 to -4.947 
HillSlope -5.305 to -3.617 
EC50 
1.028e-005 to 
1.129e-005 
Goodness of Fit   
Degrees of Freedom 86 
R² 0.9758 
Absolute Sum of Squares 847.9 
Sy.x 3.140 
Number of points   
Analyzed 90 
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Figure A-16. Dose-response curve for digitoxin 2-15a, 2-15b effect in in vitro Na+/K+ 
ATPase inhibition. IC50 values were determined by nonlinear regression analysis with 
GraphPad prism software. It was calculated with normalization to DMSO control. The 
calculated IC50 value for inhibition of the Na+/K+ ATPase activity by 2-15a, 2-15b is 3.3 
µM.  
 
 
Sigmoidal dose-response 
(variable slope)   
Best-fit values   
Bottom 0.1898 
Top 1.067 
LogEC50 -5.477 
HillSlope -1.157 
EC50 3.336e-006 
Std. Error   
Bottom 0.03112 
Top 0.009653 
LogEC50 0.04949 
HillSlope 0.1264 
95% Confidence Intervals   
Bottom 0.1279 to 0.2516 
Top 1.047 to 1.086 
LogEC50 -5.575 to -5.378 
HillSlope -1.408 to -0.9054 
EC50 
2.660e-006 to 
4.185e-006 
Goodness of Fit   
Degrees of Freedom 95 
R² 0.9532 
Absolute Sum of Squares 0.4693 
Sy.x 0.07029 
Number of points   
Analyzed 99 
 193 
 
-8.5 -7.5 -6.5 -5.5 -4.5 -3.5 -2.5
60
70
80
90
100
Log [Na3VO4]
Pe
rc
en
t C
lo
se
d 
at
 2
4 
H
ou
rs
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-17. Dose-response curve for Na3VO4 2-16 effect in MDA-MB-231 wound 
closure. IC50 values were determined by nonlinear regression analysis with GraphPad 
prism software. It was calculated for inhibition of wound closure at 24 h post-wounding 
with normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of wound 
closure at 24 h by 2-16 is 5.6 µM.  
Sigmoidal dose-
response (variable 
slope)   
Best-fit values   
Bottom 37.38 
Top 96.91 
LogEC50 -5.251 
HillSlope -0.7653 
EC50 5.613e-006 
Std. Error   
Bottom 78.49 
Top 1.473 
LogEC50 1.370 
HillSlope 0.4393 
95% Confidence 
Intervals   
Bottom -120.4 to 195.2 
Top 93.95 to 99.87 
LogEC50 -8.005 to -2.497 
HillSlope -1.648 to 0.1179 
EC50 
9.892e-009 to 
0.003185 
Goodness of Fit   
Degrees of Freedom 50 
R² 0.8371 
Absolute Sum of 
Squares 862.1 
Sy.x 4.152 
Number of points   
Analyzed 54 
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Figure A-18. Dose-response curve for Eosin 2-17 effect in MDA-MB-231  wound 
closure. IC50 values were determined by nonlinear regression analysis with GraphPad 
prism software. It was calculated for inhibition of wound closure at 24 h post-wounding 
with normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of wound 
closure at 24 h by eosin 2-17 is 34.4 µM.  
 
Sigmoidal dose-response 
(variable slope)   
Best-fit values   
Bottom 80.64 
Top 95.49 
LogEC50 -4.463 
HillSlope -0.9833 
EC50 3.441e-005 
Std. Error   
Bottom 6.457 
Top 2.935 
LogEC50 0.4537 
HillSlope 0.9908 
95% Confidence Intervals   
Bottom -1.393 to 162.7 
Top 58.21 to 132.8 
LogEC50 -10.23 to 1.302 
HillSlope -13.57 to 11.61 
EC50 5.914e-011 to 20.03 
Goodness of Fit   
Degrees of Freedom 1 
R² 0.9689 
Absolute Sum of Squares 3.650 
Sy.x 1.910 
Number of points   
Analyzed 5 
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Figure A-19. Dose-response curve for 2-18 effect in MDA-MB-231  wound closure. IC50 
values were determined by nonlinear regression analysis with GraphPad prism software. 
It was calculated for inhibition of wound closure at 24 h post-wounding with 
normalization to parallel controls using at least 5 different subtoxic concentrations in 
concentration-response experiments. The calculated IC50 value for inhibition of wound 
closure at 24 h by 2-18 is 7.86 µM.  
Sigmoidal dose-response 
(variable slope)   
Best-fit values   
Bottom 38.99 
Top 94.03 
LogEC50 -5.104 
HillSlope -0.7101 
EC50 7.864e-006 
Std. Error   
Bottom 3.428 
Top 1.234 
LogEC50 0.1067 
HillSlope 0.1047 
95% Confidence 
Intervals   
Bottom 32.15 to 45.82 
Top 91.57 to 96.49 
LogEC50 -5.317 to -4.892 
HillSlope -0.9189 to -0.5012 
EC50 4.818e-006 to 1.284e-005 
Goodness of Fit   
Degrees of Freedom 77 
R² 0.9334 
Absolute Sum of 
Squares 2042 
Sy.x 5.150 
Number of points   
Analyzed 81 
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Table A-1. Small molecule hits from chemical genetics screening of Analyticon natural 
product compound library for inhibitors of MDA-MB-231 breast cancer cell migration  
 
Structure 
Plate number – Well number 
Analyticon Code 
Comments 
 
 
 
P2-G3 
NAT13-338106 
Toxic at 50µM 
 
 
 
P2-G4 
NAT13-339685 
Not toxic (still open after 48 hrs) 
 
 
 
P2-H7 
Not toxic (still wide open after 48 
hrs) 
 
 
P4-A10 
NAT6-321371 
Not toxic 
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P5-D2 
NAT13-339050 
Toxic at 50µM 
 
 
 
P5-E2 
NAT-13338993 
Toxic at 50µM 
 
 
 
P5-E4 
NAT-15-330225 
Toxic at 50µM 
 
 
 
P5-D3 
NAT16-653195 
Not toxic 
 
 
 
P5-A5 
NAT16-653195 
Not toxic 
 P5-F4 Not toxic (still open after 48 hrs) 
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P6-A6 
NAT14-350403 
MIC – 6.25 µM; MLC – 12.5 µM 
Toxic at 50µM 
 
 
 
P6-B6 
NAT14-350423 
MIC – 6.25 µM; IC50 – 5.8 µM; 
MLC – 25 µM 
Toxic at 50µM 
 
 
 
P6-A10 
NAT17-346996 
Not toxic 
 
P7-A3 
NAT5-257066 
Not toxic (still open after 48 hr) 
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P7-A4 
NAT15-330734 
Not toxic (still open after 48 hr) 
 
P7-B4 
NAT15-330324 
Not toxic (still open after 48 hr) 
 
P8-A3 
NP-009815 
Not toxic  
 
P8-A11 
NP-004306 
Toxic at 50 µM 
 
P8-B6 
NP-010071 
Not toxic (still wide open after 
48hrs) 
 
P8-C8 
NP-002767 
Toxic at 50 µM 
 200 
 
P8-E2 
NP-005313 
Not toxic 
 
P8-E4 
NP-000518; cardiac glycoside 
(ouabain) MIC – 61 nM; IC50 – 
173 nM; MLC - >100µM 
Not toxic at 50 µM (still wide 
open after 48hrs) 
 
P8-F4 
NP-000192 
Not toxic (still wide open after 
48hrs) 
 
P8-H11 
NP-009822 
Toxic at 50 µM 
 
P9-H4 
NP-005340; cardiac glycoside 
Active from 2µM 
Not toxic at 50µM (still wide open 
after 48hrs) 
 
P8-H11 
NP-009822 
Active from 400 nM 
Toxic at 10 µM 
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P9-E6 
NP-001821 
Toxic at 50 µM 
 
P9-B10 
NP-009784 
Toxic at 50 µM 
 
P9-B10 
NP-009699 
Toxic at 50 µM 
 
P9-E10 
NP-002481 
Active from 80 nM  
Not toxic at 50µM  (still wide 
open after 48hrs) 
 
P9-G11 
NP-008014 
Toxic at 50 µM 
 
P9-A5 
NP-006205 
Not toxic 
 
P9-A11 
NP-009051 
Not toxic (still wide open after 
48hrs) 
 
P9-A11 
NP-009051 
Not toxic (slightly open after 
48hrs) 
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P9-C6 
NP-003588 
Toxic at 50 µM 
 
P9-D7 
NP-010664; colchicine 
Active from 2µM 
Not toxic at 50µM (still open after 
48hrs) 
 
P9-E9 
NP-011363 
Toxic at 50 µM 
 
P10-G4 
NP-012389 
Not toxic (still wide open after 
48hrs) 
 
P10-H6 
NP-012485 
MIC – 1.5625 µM; IC50 – 3.8 µM; 
MLC – 12.5 µM  
Toxic at 50 µM 
 
P10-G7 
NP-004022 
Not toxic (still wide open after 
48hrs) 
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P10-A8 
NP-000424 
MIC – 3.125 µM; IC50 – 5.9 µM; 
MLC – 25 µM  
Toxic at 50 µM 
 
P10-D8 
NP-007510 
MIC – 3.125 µM; IC50 – 7.6 µM; 
MLC – 25 µM  
Toxic at 50 µM 
 
P10-F8 
NP-000423 
Not toxic (still wide open after 
48hrs) 
 
P10-C9 
NP-005099; cardiac glycoside 
MIC - < 1.5625 µM; IC50 – 7.2 
µM; MLC – 25 µM  
Toxic at 50 µM 
 
P10-C11 
NP-008511; cardiac glycoside 
MIC - < 1.5625 µM; IC50 – 5.4 
µM; MLC – 5.4 µM  
Toxic at 50 µM 
 
P10-A5 
NP-007572 
Not toxic  
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P10-E11 
NP-012950 
Not toxic (slightly open after 
48hrs) 
 
P11-F3 
NP-012028 
Not toxic (still wide open after 
48hrs) 
 
P11-G3 
NP-006581 
Toxic at 50 µM 
 
P11-F7 
NP-001595 
Active from 400 nM  
Toxic at 50, 10 µM 
 
P11-H3 
NP-008189 
Toxic at 50 µM 
 
P11-G4 
NP-002480 
Active from 2µM 
Not toxic at 50µM (still wide open 
after 48hrs) 
 
P11-C5 
NP-005331; curvularin 
MIC – 3.125 µM; IC50 – 36 µM; 
MLC - > 50µM 
Not toxic at 50 µM (still wide 
open after 48hrs) 
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P11-F5 
NP-012386 
Not toxic (still wide open after 
48hrs) 
 
P4-G8 
NAT3-210762 
Not toxic 
